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Tonicity is property of a solution that is defined as the total effective (impermeable) 
osmole concentration that drives fluid movement across a semipermeable membrane via 
osmosis.  Tonicity is related to but distinct from solution osmolality, which is a summation of all 
solute concentrations, regardless of the solute membrane permeability.  In the mammalian body, 
tonicity is tightly regulated at both a cellular and systemic level; tonic derangements cause rapid 
change in cell and tissue volume leading to significant dysfunction.  Input from the central 
nervous, circulatory, endocrine, gastrointestinal, and urinary systems are integral to 
osmoregulation, so many diseases in veterinary medicine are associated with tonicity disorders.  
However, because the homeostatic mechanisms that control tonicity overlap with those 
regulating electrolyte and acid-base balance as well as hydration and vascular volume, tonic 
consequences of disease can be difficult to isolate.  Understanding of disease-associated changes 
in tonicity is further complicated by the fact that the tonic contributions of many solutes that 
accumulate in disease are unknown.  Additionally, direct assessment of tonicity is difficult 
because tonicity is not just a physiochemical property, but it implies a physiologic effect.  Thus, 
simple summation of osmole concentrations is an inadequate measurement of tonicity.   
The following report includes three studies investigating various aspects of tonicity as it 
applies to veterinary patients.  Chapter 2 reports a study that examines the tonic effects of 
ketoacids and lactate using two different in vitro red blood cell assays.  Results demonstrated that 
the ketoacids, beta-hydroxybutyrate and acetoacetate, behave as ineffective osmoles while the 
tonic behavior of lactate is variable, implying a more complex cellular handling of this anion.  
Two additional studies examine whether the mean corpuscular volume difference (dMCV) is a 
novel clinical marker for hypertonicity in dogs.  Results of separate retrospective (Chapter 3) and 
prospective (Chapter 4) studies provide evidence that dMCV is a useful clinical marker for 
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Chapter 1 - Physiology and Pathophysiology of Tonicity 
 Osmolality and Tonicity 
The terms osmolality and tonicity are often used interchangeably, however, these two 
concepts differ in subtle yet important ways.  In an aqueous solution, solutes can be classified as 
either effective osmoles or ineffective osmoles.  Effective osmoles are solutes that are 
impermeable to the cell membrane.  Because effective osmoles do not readily cross the cell 
membrane, they exert osmotic pressure causing fluid shifts between compartments that are 
separated by the semi-permeable plasma membrane.  Ineffective osmoles are solutes that are 
permeable to the cell membrane and so do not exert osmotic pressure.  Although the chemical 
properties of a solute have some influence, cell permeability is largely determined by the 
properties of the cell membrane.  The expression and concentration of various ion channels and 
substrate transporters in the cell membrane, both specific for the solute of interest and general 
non-specific transporters, determine the relative “effectiveness” of that solute as an osmole. 
 Osmolality of a solution is the term used to describe the total number of solutes 
(osmoles) per kilogram of solvent (i.e. water in biologic systems).  Osmolality is a measure of 
total solute concentration, but it does not distinguish between effective and ineffective osmoles; 
therefore, osmolality cannot accurately predict fluid shifts between the intra- and extracellular 
spaces.  Tonicity, also called effective osmolality, is the number of effective osmoles per unit of 
solvent.  Thus a change in tonicity of one fluid compartment implies that a fluid shift will occur 
across the cell membrane.  Tonicity of solutions is usually discussed in relative terms.  By 
convention, extracellular fluid (ECF) tonicity is expressed relative to that of the intracellular 
fluid.  Hypotonicity causes fluid to shift inward from the extracellular to the intracellular space; 
hypertonicity causes the opposite to occur.  In both situations, the net result is equilibration of 
tonicity between compartments with a change in the volume of both spaces.1 
 Components of Extracellular Tonicity 
The major components of extracellular osmolality and tonicity include electrolytes and 
non-ionic substances (glucose and urea).  Because the intravascular space is a sub-compartment 
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of the extracellular space and because small solutes can easily traverse the vascular wall (in most 
situations), serum solute concentrations are essentially equivalent to ECF concentrations. 
 Electrolytes 
Electrolytes are charged solutes (cations and anions) that cannot diffuse through the 
lipophilic cell membrane.  Instead, transport of electrolytes into and out of the cell is carrier 
mediated, either by ion channels or transporter proteins, which are often ATP-dependent.  Intra- 
and extracellular ion concentrations are tightly regulated so that net ion flux is zero under steady 
state conditions.  Thus ions are impermeable solutes, or effective osmoles, and, as such, 
contribute to both osmolality and tonicity.2  Sodium is the most abundant serum cation and is the 
largest contributor to serum osmolality.  Serum sodium concentration and ECF volume are 
intimately related; these values can be used to classify dehydration and hypovolemia (hypo-, iso-
, or hypertonic) and predict the direction of volume shift (intra- vs. extracellular).3  Osmosensing 
by the JGA cells in the kidneys, by the central osmoreceptors in the hypothalamus, and 
peripheral osmoreceptors in the GIT and splanchnic vasculature is largely dependent on sodium 
concentrations and determines the systemic response to changes in volume and tonicity.4,5  
Potassium also contributes to serum osmolality, but to a much smaller degree than sodium.  
Disease states characterized by severe hyperkalemia such as Addison’s disease, urethral 
obstruction, and acute kidney injury, only raise serum potassium concentration a few 
milliequivalents above normal and minimally contribute to serum osmolality.  Hypokalemia also 
has a minor effect on serum osmolality because extracellular potassium is normally maintained 
at a low concentration.  Even severe hypokalemia (2.0 mM) only lowers serum osmolality by 
approximately 4 mOsM (accounting for accompanying anions).  Other serum cations (e.g. Ca2+, 
Mg2+) also have a relatively small impact on osmolality and tonicity because they are maintained 
at low concentrations in ECF.  The effect of serum anions on serum osmolality and tonicity is 
similar to that of cations, with those of higher concentration (e.g. Cl-, HCO3-) having a greater 
impact than those of lower concentrations (e.g. phosphates, sulfates).  According to the 
principles of electroneutrality, the number of anions in solution is always equal to the number of 
cations.  Therefore, the total contribution of electrolytes to total serum osmolality is usually 
expressed as double the concentration of the major cations: 2([Na+] + [K+]).1 
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 Nonionic Osmolytes 
Nonionic solutes such as glucose and urea also contribute to serum osmolality in health, 
although their contribution is small compared to the major ionic osmoles.  Glucose and urea are 
relatively large molecules compared to the electrolytes.  Osmolality is a colligative property and 
is measured in number of particles per unit volume.  Therefore, if glucose and urea nitrogen are 
not reported in SI units, then serum concentrations must be converted using molecular weight to 
determine their osmolar contribution.1  For example, normal canine serum glucose concentration 
is approximately 100 mg/dl; this is equivalent to only 5.56 mOsM, a relatively small contribution 
when compared to normal canine sodium concentrations (150 mOsM).  However, in certain 
disease states, glucose and urea concentrations can rise several-fold and lead to significant 
hyperosmolality.  In diabetic ketoacidosis (DKA) and hyperglycemic, hyperosmolar syndrome 
(HHS), glucose concentrations are often greater than 500 mg/dl (27.8 mOsM) and can sometimes 
reach as high as  >1000 mg/dl (>55.6 mOsM) in severe cases.  Cellular glucose uptake is 
dependent on various glucose transporters (GLUT); although the rate of glucose transport is 
proportional to the expression of GLUT at the cell surface, glucose remains a relatively 
impermeable solute and an effective osmole.6  Thus hyperglycemia contributes both to 
hyperosmolality and hypertonicity.  Severe azotemia is characterized by large elevations in 
serum urea nitrogen concentrations (>200 mg/dl) and contributes significantly to serum 
hyperosmolality (>71 mOsM).  Most mammalian cells are relatively permeable to urea, due to 
the presence of a facilitated urea transporter (UT-B), making urea an ineffective osmole.7  
Therefore, azotemia does not usually contribute significantly to hypertonicity.  However, in the 
kidney, the distribution of the renal urea transporter (UT-A) varies along the different tubular 
segments.  For example, UT-A expression in inner medullary collecting duct cells is ADH 
dependent.  Without ADH, urea can act as an effective osmole in this renal tubular segment.8  
Similarly, in human patients with dialysis disequilibrium syndrome, an abrupt drop in plasma 
urea during dialysis sets up an osmolar gradient between brain cells and the interstitium, because 
of decreased UT-B expression, leading to cerebral edema and neurologic dysfunction.9 
 Osmolytes of Unknown Tonic Effect 
 Other endogenous organic substances, such as lactate and the ketoacids, are produced in 
minimal quantities in health, but can increase significantly in certain disease states.  Lactate is 
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produced by the enzymatic conversion of pyruvate by lactate dehydrogenase.  This represents an 
alternate pathway for the end products of glycolysis, when the Kreb’s cycle and the electron 
transport chain are unavailable.  Systemically, lactate is a biologic marker for anaerobic 
metabolism, due to either inadequate oxygen delivery (hypoperfusion) or inadequate oxygen 
utilization (cellular dysfunction).10  The ketoacids, β-hydroxybutyrate (BHB) and acetoacetate 
(AA), along with acetone, are synthesized from free fatty-acids via β-oxidation.  In DKA and 
starvation, ketoacids are considered to be mainly metabolic byproducts, but represent a global 
shift from predominantly carbohydrate to lipid metabolism.11  Accumulation of lactate and 
ketoacids causes a metabolic acidosis and, by definition, addition of these solutes to serum 
increases osmolality.  Although the ketoacids and lactate can permeate the cell membrane to 
some degree via facilitated diffusion through the various monocarboxylate transporters (MCT 1-
4), it is unclear whether these substances contribute significantly to serum tonicity.12  There are 
few studies that address the question of tonic influences of lactate and ketoacids.  Puliyel (2003) 
demonstrated, using a RBC osmotic fragility model, that LiAA and NaBHB prevent hemolysis in 
a manner similar to glucose at concentrations approximating physiologic serum osmolality, 
suggesting that AA and BHB act as effective osmoles.13  However, it remains unclear whether 
the ketoacids are truly effective or ineffective osmoles because the Puliyel study did not account 
for possible tonic effect of the accompanying cations (Li+ and Na+) in solution. 
 All solutes not typically measured on a routine biochemistry panel are classified as 
unmeasured osmoles.  Unmeasured osmoles can be endogenous such as lactate, ketoacids, 
uremic acids, and ammonia, or can be exogenous such as ethylene glycol, propylene glycol, 
ethanol, mannitol and various drugs.  These unmeasured osmoles constitute the osmolar gap, 
which is the difference between the measured osmolality (via osmometry) and the calculated 
osmolality (derived from serum biochemistry values).  An elevation in the osmole gap can be 
clinically useful in detecting toxicities, but can also occur in metabolic conditions.1  However, it 
is important to note that an elevation in the osmolar gap is not equivalent to serum hypertonicity 
and does not imply that significant fluid shift will occur because the true tonic nature (effective 
or ineffective osmole) of many of the unmeasured osmoles remains unknown. 
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 Tonic Stress and Mechanisms of Cellular Osmoregulation 
Virtually instantaneously after acute exposure to hypertonicity, fluid is drawn out of the 
cell and leading to cell shrinkage; conversely, acute hypotonicity causes fluid to shift inwards 
and leads to cell swelling.  In extreme situations, severe, acute hyper- and hypotonicity can lead 
to apoptosis and osmotic lysis, respectively.  However, more mild derangements of tonicity and 
cell size cause cellular dysfunction and trigger a series of compensatory changes in the cell 
leading to a regulatory volume decrease (RVD) in the case of hypotonicity, or a regulatory 
volume increase (RVI) in the case of hypertonicity.14 
Intracellular protein function is altered by hypertonicity and the resultant cell size 
decrease.  Hypertonicity causes an increase in intracellular ionic and non-ionic solute 
concentrations (e.g. urea), which can negatively impact protein function.  Similarly, the 
concentrations of intracellular proteins increase in a hypertonic state and cause macromolecular 
crowding, which alters the thermodynamic behavior of individual enzymes and transporters as 
well as molecular interactions between various proteins.15  Changes in cell size can also disrupt 
the delicate balance of the highly-organized eukaryotic cytoskeleton by inducing 
depolymerization and repolymerization of actin filaments in response to mechanical stress.2  
Protein synthesis is suppressed under hypertonic conditions through inhibition of initiation and 
elongation of the polypeptide strand.  Double-stranded DNA breaks also occur under hypertonic 
stress, which trigger the DNA damage-response systems leading to cell cycle arrest, a protective 
mechanism common to many cellular stressors.14  Finally, modest changes in cell size are an 
integral part of various hormone-cell signaling mechanisms; therefore pathologic tonic change 
may disrupt such mechanisms leading to cellular dysfunction.16 
Whether physiologic or pathologic, the cellular response to hypotonicity is cell swelling, 
which triggers mechanisms of regulatory volume decrease (RVD).  The initiators of RVD are not 
completely understood and likely differ between cell types.  In enterocytes, tyrosine cross-
phosphorylation has been identified as an essential step in RVD, whereas membrane stretch in 
hepatocytes activates Ca2+ channels, increasing intracellular Ca2+ concentration; both of these 
steps likely initiate signal transduction and activate the effectors of RVD.  Efflux of ionic 
solutes, mainly K+, Cl-, and bicarbonate, cause osmotic shift of water extracellularly and a 
subsequent decrease in cell volume.  Within minutes of hypotonic stress, all mammalian cells are 
capable of RVD resulting in complete or near-complete restoration of the original cell size.17 
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The regulatory volume increase (RVI), the cellular response triggered by hypertonicity 
and cell shrinkage, is a complex, multi-stage process.  The early response consists of ion influx 
(Na+, K+, and Cl-) mediated by pre-existing membrane transporters including the Na+-K+-2Cl- 
co-transporter, the Na+/H+ exchanger, and the Cl-/HCO3- exchanger.  Here again, the initiators of 
the RVI are not completely understood, but likely are similar to those of RVD including 
membrane stretch, changes in cytoskeletal tension, adjustment of intracellular Ca2+ 
concentration, and phosphorylation/dephosphorylation leading to activation of signal 
transduction.14  These early changes occur within seconds to minutes of tonic insult, but only 
produce partial restoration of cell size.  Not only is this early response incomplete but it results in 
an increased intracellular concentration of salts which, as previously discussed, adversely affects 
protein function.  The late response to hypertonicity involves replacement of excess intracellular 
ions with compatible osmolytes, non-ionic small molecules that do not interfere with protein 
function even at high concentrations but maintain intracellular tonicity.  These osmolytes are 
either taken up from the extracellular environment via Na+-coupled transporters (e.g. taurine, 
glutamate, GABA) or are produced endogenously via hypertonic-induced upregulation of the 
enzymatic systems required for their synthesis (e.g. glycerophosphorylcholine, sorbitol).  
Because genomic mechanisms are involved, this late response takes hours to days and, although 
it is more effective at restoring cell volume than the early response, the late response of the RVI 
does not usually result in complete volume restoration.2 
 Extracellular Fluid Tonicity and Mechanisms of Systemic Osmoregulation 
Although individual cells have the ability to adapt to moderate degrees of tonic stress, 
systemic regulation of the extracellular fluid composition constitutes a second level of defense 
against tissue dehydration and edema. These mechanisms are particularly important for organs 
such as the brain and spinal cord, which are encased within rigid bony structures.  Cellular 
swelling in these tissues leads to increased tissue hydrostatic pressure, decreased tissue 
perfusion, and risk of brain herniation during acute hypotonic insult.18  The overarching control 
system for systemic osmoregulation is, like many regulatory systems in the body, a negative 
feedback loop.  Changes in ECF tonicity are detected by specialized receptors (osmoreceptors) in 
the central nervous system and the periphery, which send neuronal impulses to the 
osmoregulatory control centers.  This input is integrated with other visceral signals, in particular 
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those detecting changes in vascular volume, and induce homeostatic adjustments by the major 
systemic effectors of osmoregulation: the ADH-pituitary-renal axis, thirst and salt appetite.5 
 Osmoregulatory Sensors: Osmoreceptors 
 The central osmoreceptors are specialized neurons located in the circumventricular 
organs of brain, which are devoid of the blood-brain-barrier.  Thus, the central osmoreceptors are 
subjected to the same tonic variation experienced by the rest of the body and undergo obligatory 
changes in cell volume.  Shrinking in response to hypertonicity increases the basal firing rate of 
osmoreceptor neurons, which send projections to other areas of the brain, communicating the 
ECF tonic status to neural control centers for the osmoregulatory effectors, including the 
supraoptic nucleus of the hypothalamus, anterior cingulate and insular cortices, and the 
parabrachial and paraventricular nuclei.  Conversely, swelling of the osmoreceptor in response to 
hypotonicity decreases the neuron firing rate.  The mechanism by which changes in cell size are 
sensed and translated into action-potentials is incompletely understood.  However, it is believed 
that the pathways involved are similar to those controlling cellular osmoregulation and initiation 
of regulatory volume changes (RVD and RVI).  Alteration of cell membrane stretch or 
cytoskeletal components in response to changes in cell size likely activate or inactive sensitive 
ion channels.  However, instead of altering the intracellular solute load and correcting cell 
volume, as occurs during regulatory volume changes, these channels alter the resting membrane 
potential of the neuron.  Because of cation influx, the cell membrane becomes less negative in 
response to hypertonicity, increasing the likelihood that an action potential will form and thus 
increasing the firing rate.  Hypotonicity causes hyperpolarization of the cell membrane, therefore 
suppressing action potential formation and decreasing the neuron firing rate.5 
 Osmoreceptors in the periphery are mostly associated with the gastrointestinal tract.  
Peripheral osmoreceptors in the oropharynx and the duodenum allow the body to sense the 
tonicity of ingesta; similarly, osmoreceptors in the splanchnic and portal circulation detect the 
osmotic content of nutrients absorbed by the intestines.  These signals are carried by vagal fibers 
to the brain and modulate the homeostatic response to body tonicity.  The net effect is that, rather 
than waiting for the absorbed fluid to equilibrate with the ECF and be detected by the central 
osmoreceptors, thirst and ADH secretion are modified in anticipation of absorption.  This 
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circumvents the several-minute delay in adjustment that would otherwise occur and buffers large 
fluctuations that might otherwise occur in response to an ingested solute load.5 
 Osmoregulatory Effectors: ADH, Thirst, and Salt Appetite 
 The major effector of systemic osmoregulation is the release of ADH and the pituitary-
renal axis.  ADH is a nine amino-acid polypeptide hormone produced by magnocellular 
neurosecretory cells (MNCs) in the supraoptic and paraventricular nuclei of the hypothalamus 
and released into the circulation from these neurons’ axon tips in the posterior pituitary gland.  
Hormone release occurs in response to hypertonicity, as sensed by the MNCs and other 
osmoreceptive neurons in the brain, and is modulated by peripheral input from GI and portal 
osmosensors via vagal afferents and the premotor cortex.  The plasma threshold for ADH release 
is ~280 mOsM in humans, below which ADH secretion is inhibited; this threshold is likely 
similar or slightly higher in dogs but has not been extensively studied.  ADH acts on V2 receptors 
present on medullary collecting duct epithelial cells in the kidney to induce fusion of endosomes 
carrying the aquaporin-2 (AQP-2) water channel with the apical cell membrane through a GS-
coupled signal transduction mechanism.  The apical AQP-2 and basolateral AQP-3 and AQP-4 
channels make the tubular epithelium permeable to water and, in the presence of an adequate 
medullary interstitial gradient, lead to concentration of the tubular fluid and reclamation of free 
water.  Excretion of concentrated urine is equivalent to a decrease in solute (effective osmoles) 
load in excess of total body water, leading to a decrease in ECF tonicity, the desired 
compensatory response to hypertonicity.  In hypotonic conditions, ADH secretion is partially or 
completely inhibited.  In the absence of ADH, the medullary collecting ducts are impermeable to 
water so no water reabsorption occurs and hypotonic urine is excreted; this causes a net loss of 
free-water and a compensatory increase in ECF tonicity.5,19 
 Thirst and salt appetite are important but opposing mechanisms involved in regulation of 
systemic tonicity.  Thirst is activated and salt appetite inhibited in hypertonic states whereas the 
opposite occurs under hypotonic conditions.  Although the central regulators of these 
mechanisms in the dog are not well established, functional imaging studies have disclosed that 
the anterior cingulate and insular cortices as well as the parabrachial and paraventricular nuclei 
appear to at least partially regulate thirst and salt appetite in humans.  As previously discussed, 
peripheral osmoreceptors, along with other visceral afferents associated with the gastrointestinal 
9 
 
tract, monitor pre-systemic changes in tonicity and modulate thirst and salt appetite in 
anticipation of salt and water absorption.5 
 Osmoregulatory and Vascular Control Integration 
 Systemic mechanisms of osmoregulation are intimately associated with vascular volume 
regulatory mechanisms.  In many cases, these responses overlap using the same regulatory 
effector systems or employing a mechanism that influences both volume and tonicity.  For 
example, non-osmotic ADH secretion can be induced by afferent signals from baroreceptors in 
response to vascular under-filling.  ADH release leads to water retention and thus expansion of 
the vascular space.  In contrast, release of the natriuretic peptides (atrial natriuretic peptide 
[ANP], brain natriuretic peptide [BNP], and C-type natriuretic peptide [CNP]) from stretched 
myocardial cells during volume expansion stimulates a primary increase glomerular filtration as 
well as inhibition of sodium resorption in the collecting ducts; the resultant natriuresis and 
diuresis decrease vascular volume.  The renin-angiotensin-aldosterone system (RAAS) also 
figures prominently in both tonic and volume regulation.  Decreased sodium delivery to the 
distal tubules stimulates renin release and subsequent angiotensin activation and aldosterone 
secretion, leading to sodium and water retention and subsequent volume expansion and increased 
plasma sodium load.3 
The net effect of these combined volume regulatory mechanisms on plasma tonicity is 
determined by the proportion of water excretion/conservation and changes in the absolute plasma 
solute load.  If water is excreted in excess of solute, plasma tonicity increases whereas if solute is 
lost in excess or water, plasma tonicity decreases.  The opposite occurs in states of fluid or solute 
retention.  Oftentimes osmoregulatory and volume-regulatory mechanisms work in concert to 
correct homeostatic perturbances.  For example, in an animal with hypovolemia and 
hypertonicity, the compensatory release of ADH benefits both conditions by retaining water in 
excess of solute, increasing plasma volume and diluting out the high concentrations of plasma 
solutes.  However, an animal that has lost solute in excess of fluid, such as with severe 
gastroenteritis, becomes hypovolemic and hypotonic.  In these situations, physiologic responses 
prioritize plasma volume at the expense of plasma tonicity – non-osmotic stimulation of ADH 
release restores plasma volume, but may temporarily exacerbate plasma hypotonicity.  However, 
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if all osmoregulatory and volume regulatory mechanisms are intact, with appropriate treatment, 
both vascular and tonic homeostasis will eventually be reached.3 
 Hypotonicity in Clinical Disease 
At a fundamental level, hypotonicity of plasma (and the ECF compartment) occurs by 
two basic mechanisms: solute loss or water gain.  The mammalian body is an aqueous system, so 
to excrete solute from the body some water must also be excreted.  Likewise, almost all water 
ingested contains some solute.  Therefore, it is more appropriate to say that the two basic 
mechanisms by which hypotonicity develops are solute loss in excess of water loss (a net solute 
loss), and water gain in excess of solute gain (a net water gain).  A variety of canine diseases are 
associated with hypotonicity; in particular, hyponatremia is often a prominent feature, given that 
sodium concentration is major determinant of plasma tonicity.3 
 Hypotonic Diseases with Solute Loss 
 Solute loss leading to hypotonicity can be classified as renal in origin or extrarenal.  A 
classic example of renal solute loss is hypoadrenocorticism in which mineralocorticoid 
deficiency prevents sodium reabsorption by the principle cells of the distal tubule and cortical 
collecting ducts of the kidney.  Hypoadrenocorticism is characterized by hyponatremia and 
hyperkalemia, reported in 82% and 85%, respectively, of patients in one study.20  Although 
hyperkalemia would tend to increase plasma tonicity, the relative magnitude compared to the 
concurrent low sodium concentration is such that there is a net decrease in ion concentration and 
thus in plasma tonicity.  Patients with hypoadrenocorticism also develop elevations in the BUN 
concentration, which contributes to an increased total plasma osmolality; however, as urea is an 
ineffective osmole, it will not contribute to plasma tonicity.  Without aldosterone, sodium 
resorption is impaired in the distal tubule as well as in the colon, increasing renal and extrarenal 
water loss.  This, along with poor vascular tone due to glucocorticoid deficit, results in a 
decreased effective circulating volume.  Decreased effective circulating volume is a potent non-
osmotic stimulus for ADH secretion (see below), which causes renal water conservation in 
excess of solute retention and may further exacerbate plasma hypotonicity.3,20-22  Similarly, 
plasma hypotonicity may occur during diuretic administration, particularly loop and thiazide 
diuretics.  Loop diuretics inhibit the Na+/K+/2Cl- symporter in the thick ascending limb of the 
loop of Henle and thiazide diuretics inhibit the Na+/Cl- symporter in the distal tubules, impairing 
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tubular electrolyte reabsorption leading to salt wasting.  Diuresis invariably ensues and, although 
compensation for this water loss may occur (through non-osmotic ADH stimulation), the 
kidney’s inability to conserve electrolytes leads to a hypotonic state.19,23 
 Extracellular solutes can also be lost through non-renal means.  Although hypotonic fluid 
loss is common during vomiting and diarrhea, hypertonic fluid can be lost through the GIT 
leading a net decrease in total body solute concentration.  Even if gastrointestinal fluid is 
hypotonic, substantial volume loss will cause vascular hypoperfusion leading to non-osmotic 
ADH secretion and hypotonic fluid retention by the collecting ducts.  Thus, either hypertonic or 
hypotonic GIT losses may lead to plasma hypotonicity.3  Although not a true total body loss of 
solute, third-spacing can compartmentalize fluids of a high solute concentration away from 
vascular and extracellular spaces leading to plasma hypotonicity.  In particular, exudates, such as 
those found in septic peritonitis and pancreatitis, can have high solute loads as does the 
abdominal effusion found during uroabdomen.3 
 Hypotonic Diseases with Water Gain 
 Hypotonicity may also occur in patients with a normal or even increased total body solute 
load, when water is conserved in excess of solute.  Although very uncommon, acute water 
intoxication causing hyponatremia and hypotonicity has been reported in a dog.24  More 
commonly, diseases associated with decreased effective circulating volume cause water 
conservation and solute dilution in veterinary patients.  In patients with heart disease, a decreased 
cardiac output is sensed by the arterial baroreceptors leading to non-osmotic stimulation of ADH 
release.  Poor renal perfusion leads to a decrease in GFR and distal tubular sodium delivery 
causing activation of the RAAS.  Both of these mechanisms induce net water retention, which 
has a dilutional effect on plasma solutes and causes hypotonicity.25  The same responses occur 
during hypoalbuminemia in patients with liver failure and nephrotic syndrome.  Low oncotic 
pressure leads to edema and third-spacing of fluid and ultimately a decrease in vascular volume.  
Hypoalbuminemic hypovolemia triggers the normal compensatory responses (non-osmotic 
stimulation of ADH and RAAS activation) leading to water retention and extracellular fluid 
dilution.25 
 Although rarely reported in veterinary patients, the syndrome of inappropriate secretion 
of antidiuretic hormone (SIADH) is the most frequent cause of hyponatremia in human patients 
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and, as sodium is the most important determinant of plasma tonicity, SIADH represents an 
important cause of hypotonicity in humans.26  The syndrome is characterized by hyponatremia, 
hypotonicity, and concentrated urine in a euvolemic patient.  The establishment of euvolemia is 
an important diagnostic criterion as elevated plasma ADH concentration is an appropriate 
response in a hypovolemic patient.  Several patterns of ADH secretion have been documented in 
SIADH including: erratic secretion of ADH; constitutively increased ADH secretion; normal 
secretion of ADH in response to an inappropriately low plasma osmolality (reset osmostat 
syndrome); and low or even undetectable concentrations of ADH with inappropriate urine 
concentration due to mutations of the V2 receptor in the renal collecting ducts.3,26  In dogs, 
SIADH has been reported both as a primary, idiopathic condition and as a sequel to other 
diseases such as heartworm infection, amebic meningoencephalitis, and congenital 
hydrocephalus.27-33  A variety of drugs are also reported to cause inappropriate release of ADH 
from the neurohypophysis (e.g. barbiturates, beta-adrenergic drugs, cholinergics, tricyclic anti-
depressants) or potentiate the response to ADH at the level of the kidney (e.g. alpha-adrenergic 
drugs, glucocorticoids) causing a temporary, SIADH-like state.3 
 Treatment of Hypotonicity 
 As with all metabolic derangements, the primary treatment goal of hypotonicity is 
amelioration of the underlying disease process.  In particular, alterations in volume status or 
oncotic pressure must be addressed, as these are often the driving force behind systemic 
hypotonicity.  In many cases, plasma hypotonicity is mild and requires no specific treatment.  
However, in cases of acute or severe hypotonicity, clinical signs associated with cerebral edema 
may occur and include lethargy, nausea, and weakness, ataxia, seizures, and coma.  In such 
cases, specific treatment to correct hypotonicity is warranted and, as hypotonicity is almost 
always accompanied by hyponatremia, is directed at correcting plasma sodium concentration.  
No optimal treatment regimen for sodium replacement has been established in the human or 
veterinary literature.  However, it is generally recommended that plasma sodium concentration 
not rise faster than 8-12 mmol/L per day, particularly in patients in whom hypotonicity is 
suspected to be chronic (>48-72 hours in duration) and are expected to have undergone complete 
cellular adaptation (RVD) to hypotonicity.  Rapid correction or overcorrection can lead to 
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myelinosis in which acute cellular dehydration causes oligodendrocyte injury and demyelination 
of axons in the pons and other areas of the brain.3,26,34 
 Hypertonicity in Clinical Disease 
Similar to hypotonicity, the mechanisms causing plasma hypertonicity can be divided 
into two major categories: water loss in excess of solute loss and solute gain in excess of water 
gain. 
 Hypertonic Diseases with Water Loss 
Water loss in excess of solute loss is caused by excretion or sequestration of fluid that is 
hypotonic to the ECF fluid and can be further divided into renal or extrarenal loss.  
Gastrointestinal losses are a common form of extrarenal hypotonic fluid loss and are caused by 
vomiting, diarrhea or in fluid sequestration that occurs during upper gastrointestinal obstruction.  
Third-spacing of hypotonic fluid can also cause plasma hypertonicity as can cutaneous losses 
such as those that occur in burn victims.  Although these hypotonic losses initially will cause 
plasma hypertonicity, if a significant enough drop in vascular volume is present, then non-
osmotic stimulation of vasopressin will occur which has a dilutional effect on plasma and may 
actually cause hypotonicity (see above).3 
 Water can also be lost by renal means.  Although patients with intrinsic kidney disease 
usually have normal sodium concentrations, fluid loss in excess of sodium can occur during 
dehydration, which would lead to hypertonicity.3  This net fluid loss may occur in patients with 
impaired sodium excretion due to tubular dysfunction and/or increased sodium retention due to 
RAAS activation.  Patients with kidney disease treated with intravenous fluids containing a high 
concentration of sodium (e.g. 0.9% NaCl) are also at risk for hypernatremia and hypertonicity, 
again, likely caused by impaired sodium excretion.3  It is important to note that azotemia can 
cause an increase in plasma osmolality due to an increased plasma urea concentration, but 
azotemia does not imply hypertonicity, as urea is an ineffective osmole.  Other solute 
concentrations that rise during uremia, such as phosphates and sulfates, may add to plasma 
tonicity, but likely do not accumulate in sufficient quantities to greatly impact total effective 
osmole concentration.  The tonic effects of creatinine have not been directly studied; it is known 
that creatinine does diffuse across cell membranes, albeit at a slower rate than urea due to its 
higher molecular weight.35,36  However, even if creatinine does exert a tonic effect, the total 
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molar concentration is unlikely to be high enough to cause significant hypertonicity, even in 
severe azotemia (e.g. [creatinine] = 20 mg/dl = 1.7 mOsM). 
 Potent renal water loss and plasma hypertonicity also occur in patients with diabetes 
insipidus.  Central diabetes insipidus (CDI), an inability to release ADH from the 
neurohypophysis, can occur both as an idiopathic or congenital disorder or secondary to neural 
damage from trauma, neoplasms, inflammatory disease, or iatrogenic damage during 
adenohypophysectomy for treatment of pituitary-dependent hyperadrenocorticism.37-41  The 
severity of CDI ranges from inadequate ADH release or appropriate ADH release at a higher 
than normal set-point (reset osmostat) to complete lack of ADH secretion.  Nephrogenic diabetes 
insipidus (NDI) has rarely been reported in dogs as a primary disease entity in which mutation of 
the V2 receptor blunts or obliterates the normal tubular response to ADH.42,43  However, 
secondary NDI, in which the action of ADH on the V2 receptor and AQP-2 channel is impaired 
by extrinsic means, occurs commonly in a variety of conditions affecting veterinary patients 
including sepsis, hyperadrenocorticism, and hypercalcemia.37  Many animals with DI are 
otherwise healthy except for severe polyuria, but are often normo- or only mildly hypertonic.  A 
compensatory polydipsia, induced by activation of the osmoregulatory thirst mechanism, negates 
the effects of this diuresis.  However, when water is withheld or the thirst mechanism is 
suppressed by concurrent disease, hypernatremia and hypertonicity rapidly ensue reaching 
concentrations in excess of 170 mmol/L and 375 mOsM, respectively.  Such severe, acute 
hypertonicity induces myelinosis, which, if not corrected, can cause ataxia, stupor, seizures, 
coma, and death.37 
 Hypertonic Diseases with Solute Gain 
 Hypertonicity can occur by a primary increase in solute load through exogenous intake or 
endogenous production of effective osmoles.  Such solutes are either measured osmoles (most 
commonly sodium or glucose), or are unmeasured osmoles of which detection requires either 
solute-specific assays or calculation of the osmole gap.  Excess ingestion of table salt or salt-
containing products can cause significant, even fatal, hypernatremia and hypertonicity.44,45  
Similarly, iatrogenic hypertonicity can occur with administration of hypertonic saline during 
which sodium concentration must be carefully monitored.3 
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In contrast to sodium, exogenous glucose administration rarely causes significant 
hyperglycemia and hypertonicity except in animals with glucose intolerance.  However, poorly 
controlled diabetes mellitus (DM) often results in clinically significant hypertonicity, particularly 
during DKA and HHS.  In one study of diabetic dogs and cats, the prevalence of effective 
hyperosmolality was 81%, with 33% exhibiting marked effective hyperosmolality (≥ 330 
mOsM).46  A second study reported mean calculated effective osmolality for cats with DM, 
DKA, and HHS as 326.5 mOsM, 316.1 mOsM, and 344.1 mOsM, respectively.47  In diabetic 
patients, an absolute or relative insulin deficiency causes poor tissue uptake of plasma glucose 
leading to profound plasma hyperglycemia.  Unconstrained by insulin and under the influence of 
counter-regulatory hormones (e.g. glucagon, cortisol, epinephrine), the liver synthesizes 
additional endogenous glucose via gluconeogenesis and glycogenolysis, further exacerbating 
hypertonicity.48 
The pathophysiology of DM is complex and solute concentrations other than glucose can 
become abnormal which may influence plasma osmolality and tonicity.49  When insulin 
concentrations are very low and glucagon and other counter-regulatory hormone concentrations 
predominate, fatty acids are liberated from adipose tissue and become substrate for ketogenesis 
in the liver.  Synthesis of the ketoacids, AA and BHB, (along with small amounts of acetone) 
represents the addition of unmeasured anions to plasma causing a normochloremic or high anion 
gap metabolic acidosis.  The presence of plasma ketoacids and metabolic acidosis are the 
hallmark features of DKA.48,50  As discussed previously, the addition of the ketoacids increases 
plasma osmolality, but the tonic effects of AA and BHB have not been well established; thus, the 
influence of the ketoacids on plasma tonicity is unknown.  Increased lactate production is also 
reported in DM and DKA, which contributes to an increased anion gap and metabolic 
acidosis.50,51  The cause of diabetic lactic acidosis is likely multifactorial.  Hypoperfusion and 
increased circulating catecholamines induce anaerobic metabolism in peripheral tissues which 
increases lactate production.10,51  Severe hyperglycemia and ketosis may also alter glucose 
metabolism, shunting glucose into the glyoxalase pathway leading to the production of D-lactate, 
the enantiomer of L-lactate, which is the normal product of anaerobic metabolism.  Increased D-
lactate concentrations have been documented in cats and humans with DM and DKA.52,53  Here 
again, this increase in lactate production can be expected to increase plasma osmolality, but the 
tonic effect of lactate is unknown; therefore, the effects of lactate on plasma tonicity are yet to be 
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determined.  In many diseases, sodium concentration is the driving force behind tonic 
derangements, however, in DM alterations in sodium may actually play a compensatory role.46  
Mild to moderate hyponatremia is relatively common in diabetic patients, due to plasma dilution 
by fluid shift into the ECF caused by the hyperglycemic osmotic gradient.48,50  One study 
documented a rise in plasma sodium concentration as hyperglycemia was corrected during DKA 
in cats.  The authors suspected that this increase in sodium was likely due to the common 
practice of using 0.9% NaCl in treatment of DKA, but noted that the increase in sodium appeared 
to mitigate rapid changes in serum tonicity that might otherwise have occurred with correction of 
hyperglycemia.54 
Hypertonicity also occurs with the addition of exogenous unmeasured effective osmoles 
to the ECF.  Perhaps the best-known example of this is ethylene glycol (EG) intoxication.  EG is 
rapidly absorbed from the GI tract and as the plasma concentration increases, so does measured 
osmolality and the osmolar gap.55  Although the high mortality rate associated with EG toxicity 
is often attributed to the acute kidney injury induced by EG metabolites later in the course of the 
disease (>48-72 hours post-ingestion), significant morbidity can occur early on in the form of 
neurologic signs caused by the ethanol-like effect of EG on the CNS as well as early and profuse 
polyuria and polydipsia secondary to hypertonicity.55,56  Propylene glycol is considered a safer 
alternative to EG as it does not cause oxalate formation and AKI.  However, at least one case of 
propylene glycol toxicity accompanied by hypertonicity and an increased osmolar gap was 
reported in a dog.57  Hypertonicity caused by addition of exogenous, unmeasured osmoles can 
also be iatrogenic and even therapeutic.  Mannitol is commonly used in both human and 
veterinary medicine to treat cerebral edema by establishing an osmotic gradient between the 
vascular space and cerebral parenchyma, drawing water out of the brain tissues, thus reducing 
intracranial pressure and the risk for brain herniation.  By the same mechanism, mannitol causes 
transient vascular volume expansion and acts as an osmotic diuretic; thus it can be used in the 
treatment of oliguric acute kidney injury.58,59 
 Hypertonicity in Human Medicine 
Thus far, hypertonicity has been discussed as a consequence of a variety of diseases.  
However, several studies in humans have investigated hypertonicity as a distinct syndrome and 
have examined the relationship between hypertonicity and a variety of clinical parameters and 
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disease states.  In one large cross-sectional study of the general population, mild (> 295 mOsM) 
and overt (> 300 mOsM) hypertonicity were found to be relatively common in adults in the 
United States with an overall prevalence of 40% and 20%, respectively.60  The risk of 
hypertonicity was significantly and positively associated with age as well as impaired glucose 
tolerance.  It was noted that hypertonicity in younger adults was associated with increased water 
intake, whereas hypertonicity in older adults was associated with decreased water intake, which 
is a known phenomenon among the elderly.  Thus, the authors suggested that there may be 
mechanisms resulting in hypertonicity in the elderly independent of diabetic status.60  Another 
study investigated the relationship between hypertonicity and obesity and found a higher 
prevalence of hypertonicity in obese adults than in adults of normal body mass.  Based on 
bioelectrical impedance data, obese individuals had a significantly higher ECF/ICF ratio, which 
was correlated with plasma sodium concentrations.  It was suggested that this altered fluid 
distribution might be caused by hypertonicity in obese adults.61  Hypertonicity may also be an 
early indicator for frailty, a condition of decreased functional reserve and vulnerability to 
morbidity, especially common in the elderly.62  A longitudinal study of older adults found that 
plasma hypertonicity was an independent predictor for the onset of disability within a four-year 
period and mortality within an eight-year period.63  Finally, hypertonicity is a particularly 
important clinical problem for insulin-resistant and diabetic patients.  In one cross-sectional 
study, the prevalence of hypertonicity in self-reported human diabetics (n = 1,239) was reported 
as 35-74%.60  In human hyperglycemic, pre-diabetic patients, hypertonicity has been shown to be 
a risk factor for progression to diabetes mellitus, with hypernatremia having an independent 
effect on disease progression.64  Similar large investigations of hypertonicity in veterinary 
patients are lacking, but could provide valuable information regarding the significance of 
hypertonicity in the general canine and feline populations. 
 Treatment of Hypertonicity 
The principles of therapy for hypertonicity are very similar to those underlying treatment 
of hypotonicity.  In cases of mild hypertonicity, no specific therapy is necessary and treatment 
should be directed at correcting the underlying disease process.  In patients with severe 
hypertonicity, solute concentrations may be directly manipulated via calculated intravenous fluid 
therapy.  A free-water deficit may be calculated and replaced using 5% dextrose in sterile water 
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(D5W).3  However, rapid correction of hypertonicity, particularly in cases where the 
hypertonicity is of long duration, carries the risk of cerebral edema, increased intracranial 
pressure, and brain herniation due to osmotic swelling of neurons in a closed space.18  In cases of 
hypertonicity due to hypernatremia, it is recommended that free-water replacement occur slowly 
over 48 hours and plasma sodium concentrations not decrease by more than 0.5 mmol/L/hr to 
decrease the risk of neurologic events.3  Some clinicians prefer to use low-sodium fluids such as 
2.5% dextrose in 0.45% NaCl ([Na+] = 77 mmol/L) or LRS ([Na+] = 128 mmol/L) rather than 
D5W for a gradual effect.  Regardless of the specific fluid chosen, serum electrolytes must be 
monitored carefully during treatment.  Correction of hypertonicity in diabetic patients requires 
fluid therapy for rehydration and volume expansion as well as insulin administration to correct 
hyperglycemia.  In human diabetics, children appear to be at much higher risk for osmotic and 
neurologic complications than adults during DKA treatment.65,66  In veterinary patients, the risk 
for cerebral edema during DKA treatment also appears low, although this may be due in part to 
the common clinical practice of treating diabetics with higher-sodium fluids.54  Normal saline 
([Na+] = 154 mmol/L) is recommended for patients with DKA due to their severe dehydration 
and the volume expanding effects of this fluid.  Additionally, the higher sodium content may 
partially compensate for the decrease in plasma glucose concentration.  Similar 
recommendations have been made for the treatment of HHS, although plasma solute 
concentrations must be even more carefully monitored as many of these patients already have 
neurologic signs caused by osmotic complications.67 
 Clinical Measurement of Osmolality and Tonicity 
Given the importance of tonic regulation in health and the sometimes disastrous 
consequences of tonicity derangement during disease, accurate assessment of plasma tonicity is 
an important clinical goal.  Unfortunately, there is no direct means to measure tonicity in 
biologic fluids.  By definition, tonicity is the summation of the concentration of all effective 
osmoles in a solution.  However, given the diverse constituents of plasma and ECF, it would be 
nearly impossible to assess each solute concentration individually.  Furthermore, the tonic effects 
of some solutes, such as ketoacids and lactate, are not well established so it is not known whether 
those concentrations should be included in the calculation of tonicity. 
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As initially discussed, osmolality and tonicity are interrelated concepts – osmolality being 
the sum total concentration of all osmoles in solution and tonicity being the total concentration of 
all effective osmoles.  If tonicity were a directly quantifiable property, then the difference 
between osmolality and tonicity would be the total concentration of all ineffective osmoles in a 
solution including measured ineffective osmoles such as urea and ineffective osmoles not 
routinely measured by the biochemistry profile.  Osmolality and tonicity also differ in that 
osmolality is solely dependent on solute concentrations whereas tonicity is contingent upon 
solute concentrations and the tonic effects of those solutes.  Because effectiveness of an osmole 
is relative to its permeability through the cell membrane, tonicity of a solution may change based 
on the surrounding tissue even though the solution osmolality remains constant.  Therefore, 
osmolality can be used to estimate tonicity with three caveats: (1) in general, osmolality 
overestimates tonicity, (2) osmolality may not be an adequate estimate during pathophysiologic 
states such as uremia in which an increased concentration of ineffective osmoles is expected, and 
(3) osmolality cannot approximate tonicity in situations where the tonic nature of the major 
osmoles are unknown. 
Osmolality can be inferred from osmotic pressure, which is one of the four colligative 
properties: vapor pressure, boiling point, freezing point, and osmotic pressure.  Colligative 
properties are properties of a solution that are solely dependent on the total number of solute 
particles in solution and are independent of the mass of those particles.  Thus, information 
regarding one colligative property of a solution may be inferred by directly measuring another.  
This is the basis for modern osmometric techniques.  Vapor pressure osmometry measures 
changes in the dew point of a solution and compares it against standards to determine the 
osmolality of that solution.  However, vapor pressure osmometry is technically difficult and 
cannot be used in the presence of volatile solutes such as ethanol.  The alternative technique is 
freezing point depression osmometry.  In osmometry by freezing point depression, the sample is 
supercooled and stirred to initiate crystallization.  The temperature then rises due to release of 
latent heat from crystallization and this temperature is compared against a set of standards.  
Freezing point depression osmometry is considered to be more precise than vapor pressure 




Direct measurement of total osmolality requires specialized equipment, which may not be 
readily accessible in all clinical situations.  Therefore, a variety of equations have been proposed 
to estimate total osmolar concentration in the form of calculated osmolality.  Most formulas for 
calculated osmolality (OsMC) incorporate the major cations (Na+ and K+, or Na+ alone) 
multiplied by a coefficient, usually 2.0, to account for accompanying anions; those formulas that 
use a lower coefficient (e.g. 1.86) do so to represent incomplete dissociation of salts.  Glucose 
and BUN are usually included and divided by a conversion factor (18 and 2.8, respectively) to 
convert from mass to molar units.  A constant is sometimes added to account for unmeasured 
osmoles such as Ca2+, Mg2+, PO43-, and lactate in solution.  Some published equations also 
divide the entire summation by a factor (usually 0.92 – 0.93), as this is the percentage of plasma 
that is aqueous, the rest of the plasma suspension being comprised of protein and lipids.  Several 
studies in humans and animals have compared calculated osmolality formulas to determine 
which best approximates measured osmolality and minimizes osmole gap.69-72  For dogs, Barr 
and Pesillo-Crosby (2008) recommended the traditional formula: OsMC = 2(Na+ + K+) + 
BUN/2.8 + glucose/18, for ease of clinical use and because its performance for estimating 
measured osmolality was second best among formulas investigated, closely following a much 
more complex equation.71  In a similar study in cats, exclusion of potassium concentration from 
the formula (OsMC = 2(Na+) + BUN/2.8 + glucose/18) yielded superior results.72  Although 
formulas for calculated osmolality may estimate measured osmolality well, it is difficult to 
predict how they may perform for estimating tonicity.  The formulas recommended for use in 
cats and dogs do not include terms to account for osmoles not traditionally measured including 
those that may have tonic effect.  In this way, calculated osmolality may underestimate tonicity.  
However, by including measured ineffective osmoles (i.e. BUN), calculated osmolality may 
overestimate tonicity, particularly in conditions associated with increase ineffective osmolar 
concentrations (e.g. kidney disease).  This second limitation may be remedied by excluding the 
BUN concentration from the estimate, a value known as calculated effective osmolality (OsMCE 
= 2(Na+ + K+) + glucose/18).  Unfortunately, because of exclusion of unmeasured effective 
osmoles, calculated effective osmolality likely underestimates true effective osmolality – 
tonicity.  Formulas for calculated effective osmolality are included in many of these osmolality 
studies, but do not appear to perform as well as those formulas for calculated osmolality.69,70,72  
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However, this is to be expected because the gold standard used in these studies is measured 
osmolality, not tonicity – for which there is no gold standard of measurement. 
 By definition, changes in the tonicity of a biologic solution will cause changes in the size 
of cells immersed in that solution.  This physiologic effect of tonicity may open new avenues of 
investigation for measuring tonicity.  Instead of attempting to directly measure the total effective 
osmole concentration, it might be possible to measure the physiologic effect of those osmoles by 
detecting changes in cell size and then extrapolating the tonicity of the solution from the 
behavior of the cells.  The mammalian red blood cell (RBC) is an easily harvestable and 
measureable cell that has been used in many classic fluid physiology experiments.73-77  RBCs 
have also been used in osmotic fragility assays specifically investigating the effects of various 
solutes of importance in diabetes mellitus.13,78  The endpoint for RBCs in these studies was 
hemolysis due to cell swelling from hypotonicity.  However, hemolysis assays are insensitive to 
small increases in cell size (mild hypotonicity) and are completely unable to detect cell shrinking 
due to hypertonicity.  With modern techniques, it is possible to detect smaller changes in cell size 
that could correspond to changes in extracellular tonicity.  Spurious elevation of erythrocyte 
mean corpuscular volume (MCV) is a well characterized lab error that occurs when blood from 
hypertonic patients is assessed by an automated cell analyzer.  In vivo, RBCs are acclimated to 
the hypertonic patient serum.  In vitro, when RBCs from hypertonic patients are placed into the 
isotonic analyzer media (~300 mOsM), they swell because the analyzer solution is relatively 
hypotonic to the intracellular environment causing an intracellular fluid shift.79  Stookey et al. 
(2007) exploited this “lab error” to develop a new index for plasma hypertonicity, the MCV 
difference (dMCV).80  The dMCV is the difference between the MCV as measured by an 
automated cell analyzer and the MCV calculated from a spun hct, which is performed with RBCs 
in the original patient plasma (dMCV = MCVM – hct x 10/[RBC]).  A cutoff value of only 2 fl or 
greater for dMCV performed well as an indicator for hypertonicity and, when combined with an 
elevated plasma vasopressin concentration, yielded 100% sensitivity and specificity.80 
Use of the RBC as a detector of tonicity may yield valuable information for veterinary 
practitioners and researchers.  However, it does have some potential limitations because RBC 
size is not solely governed by tonicity.  Part of this phenomenon may be due to the biconcave 
shape of the mammalian erythrocyte.  Changes in cell volume alter the conformation of the 
erythrocyte cytoskeleton leading to a change in cell membrane curvature.81  Therefore, if cell 
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volume is derived from measurements of cell diameter, volume may be underestimated.  This 
problem is circumvented by a ‘sphering’ treatment to produce homogenous RBC spheres prior to 
analysis.  The sphering technique is standard practice for most RBC analyzers used in clinical 
pathology laboratories and has been shown to render accurate and repeatable measurements of 
RBC size.82  Plasma and intracellular proteins exert an effect on fluid balance through oncotic 
pressure, which varies according to size, structure, and charge of the protein moieties.  Because 
changes in net oncotic pressure can elicit fluid shifts independently of tonicity, plasma protein 
concentrations may alter cell size (in either direction) from values predicted based on plasma 
tonicity alone.1  Albumin is the most important plasma determinant of oncotic pressure, 
contributing approximately 80% of the total plasma colloid osmotic pressure.1  Finally, and most 
importantly, all mammalian cells have the ability to regulate volume through the RVD and RVI.  
Complete regulatory responses take time to occur (hours to days) so studies examining acute 
RBC volume changes will likely yield valid information about tonic effects.  However, 





Chapter 2 - Tonic Effects of Ketones and Lactate Assessed Using 
Two Canine Red Blood Cell Assays  
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 Abstract 
Objective: To establish the tonic effects of β-hydroxybutyrate (BHB), acetoacetate (AA), and 
lactate. 
Procedures: Two in vitro models were used.  The modified osmotic fragility assay measured the 
ability of ketoacids salts added to serial sucrose dilutions to protect red blood cells (RBCs) from 
osmotic hemolysis.  The sucrose concentration at which 50% hemolysis occurred under control 
conditions was designated the H50.  In a second assay, a handheld cell counting device measured 
changes in RBC diameter (dRBC) to assess the tonic effect of solutions of ketoacid and lactate 
salts. 
Results: In the modified osmotic fragility assay, addition of sodium BHB or lithium AA yielded 
a lower H50 than the control sucrose series indicating an osmoprotective effect.  All ketoacid 
salts demonstrated an osmoprotective effect; however the effect was determined to be completely 
attributable to the tonic effect of added cations (sodium and lithium), not the ketoacid moieties.  
In the dRBC assay, the dRBC was significantly increased with the addition of urea (an 
ineffective osmole), but did not change with the addition of glucose (an effective osmole).  The 
dRBC was significantly increased over controls by addition of sodium BHB, lithium AA, and 
lithium lactate but was not increased by sodium lactate. 
Conclusions: In both assays, BHB and AA act as ineffective osmoles.  The tonic effects of 
lactate were complex and differed with the accompanying cation. 
 Introduction 
 The terms osmolality and tonicity are often used interchangeably; however, these two 
concepts differ in subtle yet important ways.  Osmolality is the term used to describe the total 
solute concentration, but does not distinguish between solutes that exert osmotic pressure 
(effective osmoles), those that do not (ineffective osmoles).  The barrier function of the cell 
membrane is an essential component in the generation of an osmotic gradient and the ability to 
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exert osmotic pressure depends on the permeability of the cell membrane to a given osmole.  
Tonicity, also called effective osmolality, is the number of effective osmoles per unit of solvent.1  
When ineffective osmoles are added to the solution surrounding cells, cells undergo a rapid 
volume increase as new osmoles diffuse into the cells and water follows.  However, when 
effective osmoles are added, cells shrink as intracellular water is drawn across the semi-
permeable cell membrane via osmosis.  Hypertonicity can lead to significant cellular 
dysfunction.  Loss of intracellular water causes macromolecular crowding within the cell and 
dysregulation of intracellular proteins.15  Changes in cell size are a normal part of cell signaling 
in many tissues and thus shrinking induced by pathologic hypertonicity will disrupt these 
pathways.2  Finally, cells acclimatized to chronic hypertonicity can swell during rapid correction 
of serum tonicity leading to tissue edema.18 
In health, the major contributors to serum tonicity include the monovalent ions and 
glucose.  In many disease states, hypertonicity results from an increased serum concentration of 
endogenous or exogenous effective osmoles.  Diabetes mellitus is an important cause of 
hypertonicity, resulting from hyperglycemia, in both humans and animals.  The prevalence of 
hypertonicity in human diabetics varies depending on the cut-off value used to define 
hypertonicity.  In one cross-sectional study, the prevalence in human diabetics was reported as 
35-78%; a similar value has been reported in diabetic dogs and cats (33-81%).46,60  In addition to 
glucose, sodium concentration also appears to be an important contributor to hypertonicity in 
human and veterinary patients and may independently impact diabetic progression.46,54,64  
Diabetic patients may also have excess accumulation of endogenous osmoles that normally are 
maintained at minute concentrations in healthy patients.  Examples of these solutes are the 
ketoacids, BHB and AA, which are overproduced in unregulated diabetes mellitus by the liver as 
an indirect consequence of relative or absolute insulin deficiency.11,48,83  lactate concentration 
can also increase, particularly, during diabetic ketoacidosis, owing to hypoperfusion and altered 
glucose metabolism.51  These solutes increase serum osmolality, but it is unclear whether they 
increase serum tonicity by acting as effective osmoles. 
Comazzi et al (2004) investigated the effects of glucose, with or without ketoacids, on a 
variety of canine RBC parameters including size and osmotic fragility.  They found that changes 
in these parameters were significantly greater when both glucose and NaBHB were added, 
compared with the addition of glucose alone.78  Using an osmotic fragility assay with human 
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RBCs, Puliyel (2003) concluded that AA is an effective osmole because LiAA protected RBCs 
from hypotonic-induced lysis in a manner similar to that of the known effective osmoles, NaCl 
and glucose.13  However, the methodologies used in previous investigations added ketoacids to 
solutions as Na+ or Li+ salts of the weak organic acid and tonic effects of added cations may have 
confounded the analysis.  Thus, the tonic effects of the organic anions remain to be firmly 
established. 
The present study examined the hypothesis that organic anions (BHB, AA, lactate) are 
ineffective osmoles and do not exert a tonic effect.  The hypothesis was investigated using two 
methods to assess tonic effects of various organic osmoles while excluding the effects of 
accompanying cations.  First, a modified RBC osmotic fragility assay was used to compare tonic 
effects of organic salts of ketoacids (NaBHB and LiAA) with inorganic salts (NaCl and LiCl).  
Second, a novel canine red blood cell assay was used to compare changes in dRBC in the 
presence of osmoles of known (glucose, urea) and unknown (BHB, AA, lactate) effect.   
 Materials and Methods 
 Modified Osmotic Fragility Assay 
Canine RBCs in EDTA (drawn < 48 hours and kept at 4 °C) were centrifuged at 1200 
rpm for 10 minutes, followed by three serial 1:3 washings with 300 mOsM NaCl.  The final 
supernatant was discarded and 100 µl of pelleted cells were resuspended in 500 µl of each test or 
control solution.  Cells were incubated for 10 minutes at 22 °C and then centrifuged at 2000 rpm 
for three minutes and the pellet was discarded.  As a marker for cell lysis, the free hemoglobin 
content of 100 µl of each solution was measured by spectral absorbance (λ = 450 nm) using a 96-
well plate spectrophotometer.a  Samples were analyzed in duplicate and values were expressed as 
% hemolysis, using RBCs incubated in double-distilled water to represent 100% hemolysis (Eq. 
2.1). 
Eq. 2.1   %  ℎ𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠 =    !"#$%&  !"  !"#$%"&  !.!.
!!!!!  !.!.
  𝑥  100 
 First, the relative tonicities of the ketoacid salts (NaBHB and LiAA) were compared to 
their respective Cl- salts (NaCl and LiCl) by assessing their ability to protect RBCs from 
                                                
a SpectraMax190; Molecular Devices; Sunnyvale, CA 
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hypotonic-induced hemolysis.b  A series of sucrose solutions were prepared in 50mM increments 
(0 mM – 300 mM) in triplicate.  To each series, either 50 mM NaBHB or 50 mM NaCl, or were 
added and assayed as described above; and unadulterated sucrose series was used as control.  An 
identical procedure was performed using LiAA and LiCl.  The control series (sucrose) was 
performed four times and each non-control series (NaBHB, NaCl, LiAA, LiCl) was performed 
eight times; the mean for each data point was calculated.  From these means, hemolysis 
protection curves for each series were generated by plotting the % hemolysis (y-axis) of each 
sample/control against the sucrose concentration of each solution (x-axis).  For each curve, the 
sucrose concentration at which 50% hemolysis occurred (H50) was visually determined and 
compared between NaBHB and NaCl and between LiAA and LiCl as well as to the H50 for the 
control (sucrose) solution.  An H50 lower than that of the control series indicated an 
osmoprotective (tonic) effect of the added (non-sucrose) solutes. 
 Next, the H50s of the control solution, NaCl, and NaBHB were compared to assess 
whether the BHB anion exerts a tonic effect independent of the sodium cation.  The number of 
non-sucrose, effective osmoles added to the NaCl-containing series as determined by the osmotic 
fragility assay, was calculated by subtracting the H50 of the NaCl solution from H50 of the 
control solution.  This difference was divided by the number of non-sucrose, effective osmoles 
known to be added to each solution (i.e. 50 mM NaCl = 100 mOsM) to establish a correction 
factor for the assay (Eq. 2.2). 
Eq. 2.2 𝐴𝑠𝑠𝑎𝑦  𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑖𝑜𝑛  𝐹𝑎𝑐𝑡𝑜𝑟 =   !!"   !"#$%"& !  !!"  (!"#$)
!""  !"#$
 
The difference between the H50 of the control series and the H50 of the NaBHB-
containing series was multiplied by the assay correction factor to determine the number of non-
sucrose, effective osmoles added to solution by 50 mM NaBHB.  It was assumed that, if BHB is 
an effective osmole, then NaBHB would contribute two effective osmoles per mole salt (50 mM 
NaBHB = 100 mOsM), representing the tonic contribution of both Na+ and BHB.  However, if 
BHB is an ineffective osmole, then NaBHB would contribute only one effective osmole per mole 
salt (50 mM NaBHB = 50 mOsM), representing only the tonic contribution of sodium.  A similar 
analysis was performed for LiAA and LiCl. 
                                                
b NaCl, NaBHB, NaLactate, LiCl, LiAA, LiLactate, sucrose, urea; Sigma-Aldrich; St. Louis, MO 
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 Canine dRBC Assay 
Canine RBCs in EDTA (drawn within 36 hours and kept at 4 °C) were prepared by 
washing in a 1:5 dilution with 0.01 M phosphate buffered saline.  The cells were mixed and 
centrifuged at 1050 rpm for five minutes and the supernatant discarded.  The wash step was 
repeated and the cell pellet was then re-suspended in a 1:1 volume of 300 mOsM NaCl.c  An 
aliquot of suspended RBCs was diluted 1:20 into 300 mOsM NaCl and acclimated for at least 10 
minutes at 22 °C. 
An aliquot (1 µl) of acclimated RBCs was added to 500 µl of control or test solutions and 
incubated for 30 minutes at 22 °C.  The dRBC of cells in each solution was measured using a 
hand-held automated cell counting device.d  After gentle mixing, a 100 µl sample containing 
RBCs was aspirated into a disposable 40 µm sensor attached to the cell counting device.  Cell 
counts stratified by cell diameter in the form of a histogram were automatically generated by the 
cell counting device.  Data were downloaded and imported into the cell counting device 
softwaree and the histograms were gated.  Gating was performed manually by selecting the first 
bin from both ends of the range that was taller than it was wide (Figure 2.1).  Mean cell dRBC 
was then calculated by the software and exported to a spreadsheetf for data analysis. 
 
  
                                                
c Standard Solution, 300 mOsm/kg H2O; Precision Systems; Natick, MA 
d Scepter 2.0; EMD Millipore; Haywood, CA 
e Scepter Software Pro 2.0; EMD Millipore; Haywood, CA 
f Excel; Microsoft; Redmond, WA 
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Figure 2.1  Histogram output of the hand-held cell counting device.  Gating was performed 
manually by selecting the first bin from both ends of the range that was taller than it was 
wide.  In this example, the upper gating is appropriate; the lower gate would be manually 
set to one bin higher. 
 
 
First, osmoles of known tonic effect were assayed to define the behavior of effective and 
ineffective osmoles in the canine dRBC assay.  A 50 mM solution of a known effective osmole, 
glucose, was prepared in 300 mOsM NaCl.  Similarly, a 50 mM solution of a known ineffective 
osmole, urea, was prepared in 300 mOsM NaCl.  The dRBCs of these solutions, as measured by 
the canine RBC assay were, compared to a 300 mOsM NaCl control solution. 
Next, the tonic effects of BHB, AA, and lactate were examined.  The effects on dRBC of 
300 mOsM solutions of NaBHB and NaLactate were compared with a 300 mOsM NaCl control 
solution.  Because NaAA was not readily available, AA was tested using the Li salt.  Three 
hundred mOsM solutions of LiAA and LiLactate were prepared and compared to a 300 mOsM 
LiCl control solution.  All experiments were performed in replicate (n = 15-18 replicates).  The 
dRBC value for all solutions was expressed as mean ± standard deviation.  The Wilcoxon rank 





 Modified Osmotic Fragility Assay 
 Hemolysis protection curves for NaBHB and NaCl are displayed in Figure 2.2.  All 
curves demonstrated a clear progression from 0% hemolysis (300 mM sucrose) to 100% 
hemolysis (0 mM sucrose).  The H50 for both NaBHB (78 mM sucrose) and NaCl (31 mM 
sucrose) were lower than that for the sucrose control (130 mM sucrose); however, the H50 for 
NaCl was lower than that for NaBHB. 
 
Figure 2.2  Hemolysis protection curves for NaCl and NaBHB containing series relative to 
control.  The vertical thin dotted lines represent the sucrose concentration at which 50% 
hemolysis occurs (H50) for each series.  The horizontal thin dotted lines represent the 
differences between the H50 of NaCl, NaBHB, and control and thus the amount of non-
sucrose, effective osmoles added to each series. 
 
 
Similar relationships were evident between the H50s of LiAA (87 mM sucrose), LiCl (31 mM 
























Figure 2.3  Hemolysis protection curves for LiCl and LiAA containing series relative to 
control.  The vertical thin dotted line represents the sucrose concentration at which 50% 
hemolysis occurs (H50) for each series.  The horizontal thin dotted lines represent the 
differences between the H50 of LiCl, LiAA, and control and thus the amount of non-
sucrose, effective osmoles added to each series. 
 
 
 The correction factor for the osmotic fragility assay using sodium salts was determined to 
be 0.99.  Therefore, the corrected number of non-sucrose, effective osmoles added to solution by 
of 50 mM NaBHB was calculated as 51 mOsM (0.99 x [130 mM – 78 mM]).  This value is 
almost exactly the number of effective osmoles expected to be added when assuming NaBHB 
only contributes a single effective osmole per mole salt (50 mOsM).  The correction factor for 
the osmotic fragility assay using lithium salts was also 0.99.  Therefore, the corrected number of 
non-sucrose, effective osmoles added to solution by 50 mM of LiAA was calculated as 42 
mOsM (0.99 x [130 mM – 87 mM]).  This value is closest to the number of effective osmoles 
expected to be added when assuming LiAA only contributes a single effective osmole per mole 
























 Canine dRBC Assay  
 Osmoles of Known Tonic Effect 
The results of these experiments are displayed in Figure 2.4.  The dRBC in the glucose-
containing solution (4.39 µm ± 0.067) was smaller than the dRBC in the NaCl control solution 
(4.40 µm ± 0.076), but this difference was not statistically significant (p = 0.56).  However, the 
dRBC in the urea-containing solution (4.50 µm ± 0.088) was significantly larger compared with 
the NaCl control (p = 0.014). 
 
Figure 2.4  dRBCs for osmoles of known tonic effect (50 mM urea or glucose in 300 mOsM 
NaCl).  Addition of the ineffective osmole, urea, causes a significant increase in dRBC (4.50 
µm ± 0.088) compared to saline control (4.40 µm ± 0.076).  Addition of the effective osmole, 
glucose, does not significantly change dRBC (4.39 µm ± 0.067) relative to control. 
 
 Osmoles of Unknown Tonic Effect (BHB, AA, and lactate) 
The results of these experiments are displayed in Figure 2.5.  The dRBC in the NaBHB 
solution (5.43 µm + 0.394) was significantly larger compared with the NaCl control solution 
(4.52 µm + 0.190; p < 0.001).  In contrast, dRBC in the NaLactate solution (4.33 µm + 0.335) 
was significantly smaller compared with the NaCl control (p < 0.001).  The dRBC in both the 
LiAA solution (5.09 µm + 0.194) and the LiLactate solution (4.33 µm + 0.335) were 





Figure 2.5  Tonic effects of unknown osmoles on red blood cell diameter (dRBC) in sodium 
salts (panel A) and lithium salts (panel B); 150 mM (300 mOsM) concentrations for all 
solutions.  dRBC for NaBHB (5.43 µm + 0.394), LiAA (5.09 µm + 0.194), and LiLactate 
(5.09 µm + 0.194) are statistically greater compared to their relative controls (NaCl 4.52 
µm + 0.190; LiCl 3.97 µm + 0.239) in a manner similar to the ineffective osmole, urea.  The 
dRBC for NaLactate (4.33 µm + 0.335) was not larger than control, in a manner similar to 




 The results support the hypothesis that the ketoacids (BHB and AA), act as ineffective 
osmoles and therefore do not exert a tonic effect.  When tested using the modified osmotic 
fragility assay, both the NaCl and the NaBHB series had higher H50 values compared to the 
control (sucrose) series, indicating that the addition of either NaCl or NaBHB exerted an 
osmoprotective effect.  The same effect on H50 was detected in experiments comparing LiCl and 
LiAA against sucrose alone.  This finding was expected since the addition of 50 mM NaCl or 
LiCl, which are known to be effective osmoles, increases the tonicity of the sucrose solutions 
and reduces the osmotic gradient across the RBC membrane, decreasing the likelihood of lysis.  
Comparison of the H50 value for the NaCl/NaBHB and LiCl/LiAA series permits the specific 
effect of the anion (BHB and AA) to be determined.  Addition of 50 mM NaCl or LiCl increases 
tonicity by 100 mOsM because these salts dissociate completely in aqueous solution.  Like all 
salts, NaBHB and LiAA also dissociate completely in aqueous solution. If BHB is an effective 
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osmole, 50 mM NaBHB would increase tonicity by 100 mOsM, but if BHB behaved as an 
ineffective osmole, 50 mM NaBHB would only increase tonicity by 50 mOsM; the same is true 
for LiAA solutions.   In both series, the osmoprotective effect of the ketoacid salts was less than 
the corresponding chloride salt, suggesting that each ketoacid salt did not contribute the same 
number of effective osmoles as the corresponding chloride salt.  Calculation of a correction 
factor allowed for the tonic effects of ketoacids to be distinguished from those of the Na+ and Li+ 
cations.  The concentrations of effective osmoles added by 50 mM NaBHB and 50 mM LiAA 
were 51 mOsM and 42 mOsM, respectively, which are both close to 50 mOsM, the expected 
value if BHB and AA are ineffective osmoles.  Thus, the results of the modified fragility assay 
support the conclusion that BHB and AA act as ineffective osmoles and do not exert tonic 
effects. 
In a second series of experiments, the effects of urea and glucose were assessed using a 
novel assay to determine changes in RBC diameter (dRBC).  The dRBC was increased 
significantly by addition of urea, an ineffective osmole.  The increase in dRBC was expected 
because RBCs are highly permeable to urea.7  Influx of urea is accompanied by water causing 
swelling of the cells and increasing the dRBC.  Exposure to glucose, a known effective osmole, 
was expected to decrease dRBC through an opposite mechanism that encouraged water efflux 
and decreased cell size.  In experiments using glucose, the dRBC decreased relative to control 
but the difference did not reach statistical significance.  The reason for the reduced effect of 
glucose under test conditions is not clear but could be related to the complex handling of glucose 
by canine RBCs.  It has been reported that glucose transport into canine RBCs is higher than in 
many other species.84  It is possible that a high intracellular glucose concentration opposed the 
transcellular gradient induced by glucose incubation, reducing the tonic effect of the extracellular 
glucose. Regardless, the urea and glucose experiments demonstrated the expected changes in 
dRBC in the presence of ineffective and effective osmoles. 
Incubation with NaBHB and LiAA significantly increased dRBC compared with control 
solutions of NaCl and LiCl.  The changes in dRBC caused by solutions of ketoacids are 
consistent with the changes caused by incubation with urea, suggesting these substances act as 
ineffective osmoles.  This is in accordance with the hypothesis and the results from the modified 
fragility assay.   The changes in dRBC caused by lactate, however, were discordant.  NaLactate 
caused a decrease in dRBC relative to the NaCl control, consistent with action as an effective 
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osmole, whereas LiLactate caused an increase in dRBC compared with the LiCl control, 
consistent with action as an ineffective osmole.  It is not clear why lactate appears to function 
differently when paired with different cations.  The Li+ concentration in these in vitro solutions 
far exceeds that normally experienced by RBCs and may affect cell membrane function in 
unpredictable ways.  For example, Li+ could alter the function of the MCT, which facilitate 
lactate cell entry.12  The MCTs also mediate transport of the ketoacids, so the tonic effect of AA, 
which was measured as a Li+ salt, might also be affected by the supranormal Li+ concentration.  
Unfortunately, AA is not readily available as a sodium salt so comparisons between the sodium 
and lithium salts of AA could not be determined. 
 Although tonicity is often discussed at a systemic level (e.g. serum tonicity), there can be 
significant variability in tonic effect when examining individual tissues and cells.  The tonic 
behaviors of effective and ineffective osmoles are not solely dependent on the chemical 
properties of the solute such as charge, size and hydrophobicity.  Tonic behavior is also 
dependent on tissue characteristics and the properties of the cell membrane.  It is apparent that 
the tonic effects of osmoles can vary in different situations.  For example, urea acts as an 
ineffective osmole in most tissues because most cells have abundant expression of urea transport 
proteins, which allows for fast equilibration of urea across the cell membrane.7  However, in the 
renal tubules there is differential expression of the urea transporter, which is under hormonal 
regulation.  Under certain conditions in the tubule, urea can behave as an effective osmole, which 
is an important mechanism for tubular fluid dilution.8  Similarly, in most tissues, especially 
muscle, membrane localization of the glucose transporter, GLUT 4, is regulated by insulin.6  In 
the absence of insulin or in insulin-resistant states (i.e. diabetes mellitus), the cell becomes even 
less permeable to glucose, which presumably increases the tonic effects of glucose.  Cell 
permeability to ketoacids and lactate may also be modulated by differences in MCT protein 
expression, especially MCTs 1-4.  The various MCT isoforms have different substrate affinities 
and there is differential expression of these transporters among tissues.  Furthermore, MCT 
expression and activity is regulated by a variety of pathways that may be influenced by the 
intracellular milieu.12   
 A limitation of this study is that only RBCs were studied.  As previously discussed, tonic 
effects of solutes may vary by tissue type and disease state, so the effects of the ketoacids and 
lactate on RBCs may not represent the response seen in all cell types.  RBCs were used for 
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practical reasons due to ease of sample collection and handling but RBCs also serve as a classic 
model for biologic osmolality studies.73,74  However, other cells line could be considered in 
future experiments to assess effects on target tissues that are particularly susceptible to tonic 
injury, such as neural tissues.18  The test solutions used in these experiments were simple iso- or 
hypertonic aqueous solutions, which were needed to isolate the effects of individual osmoles.  
Ideally, dRBC would have been measured in solutions that approximate the composition of 
serum or interstitial fluid.  Serum was not used for dRBC experiments due to technical 
limitations of the cell counting device used to determine dRBC.  Similarly, technical limitations 
also precluded evaluation of RBCs in hypotonic solutions.  Finally, the results reflect the tonic 
effects on RBCs in vitro. Given the variability and diversity of biologic systems, extrapolations 
to clinical situations should be made with caution. 
 In conclusion, BHB and AA act as ineffective osmoles in a biologic model.  The tonic 
effects of lactate are complex and may be influenced by the cation concentration.  These 
experiments used ketoacid and lactate concentrations that exceed those found in healthy dogs 
and reported for various disease states.  Based on these findings, it is predicted that BHB or AA 
do not contribute to serum tonicity in clinical syndromes, such as diabetes or ketoacidosis.  
Similarly, lactate is unlikely to exert a strong tonic effect but elucidating the mechanism of the 





Chapter 3 - In Vitro Increase of Mean Corpuscular Volume 
Difference (dMCV) as a Marker for Serum Hypertonicity in Dogs 
Jennifer M. Reinhart, Misty R. Yancey, Lisa M. Pohlman, Thomas Schermerhorn 
 Abstract 
Spurious increase in erythrocyte mean corpuscular volume (MCV) on automated cell 
analyzers is a well-characterized lab error in hypertonic patients.  A difference between 
automated and manual MCV (dMCV) greater than 2 fl has been shown to predict hypertonicity 
in humans.  The purpose of this study was to investigate dMCV as a marker for serum 
hypertonicity in dogs and to examine the relationship between dMCV and three methods of 
estimating serum tonicity: measured (OsMM), calculated (OsMC), and calculated effective 
(OsMCE) osmolalities.  OsMC, OsMCE, and dMCV were calculated from routine blood values and 
OsMM was directly measured in 121 dogs.  The dMCV of hypertonic dogs was significantly 
larger than that of normotonic dogs for all three osmolality methods.  dMCV predicted 
hypertonicity as estimated by OsMM better than it predicted hypertonicity as estimated by OsMC 
and OsMCE.  A cutoff of 2.96 fl yielded the best sensitivity (76%) and specificity (71%) for 
hypertonicity estimated by OsMM. 
 Introduction 
Serum hypertonicity is an important clinical problem in both human and veterinary 
medicine.  Hypertonicity, also known as effective hyperosmolality, is defined as an elevated 
serum concentration of solutes that draw fluid out of cells by osmosis (i.e. effective osmoles or 
osmoles with tonic effect).1  At a tissue level, hypertonicity can lead to cellular dysfunction by 
altered function of the protein macromolecular apparatus, decreased protein synthesis, changes in 
cell membrane function, and breaks in nucleic acid strands.2,14,15  At a systemic level, 
hypertonicity is associated with a variety of clinical conditions and has been investigated as an 
early indicator for progression of several disease states.46,54,60-64 
In the Third National Health and Nutrition Examination Survey (NHANES III), a cross-
sectional survey of nonhospitalized individuals, the prevalence of hypertonicity (OsM  ≥ 300 
mOsM) in human adults in the U.S. is estimated at 20% with borderline hypertonicity (OsM = 
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295-300 mOsM) affecting an additional 40% of the population.60  Higher prevalence has been 
associated with age, obesity, race, and diabetic status.60,61  Hypertonicity may also be an early 
indicator for frailty, a condition of decreased functional reserve of the body and vulnerability to 
systemic morbidity, especially common in the elderly.62,63  A longitudinal study of older adults 
found that plasma hypertonicity was an independent predictor for the onset of disability within a 
4-year period and mortality within an 8-year period.63  Hypertonicity is a particularly important 
clinical problem for insulin-resistant and diabetic patients.  In NHANES III, the prevalence of 
hypertonicity in human diabetics (identified by fasting glucose or oral glucose tolerance test or 
by self-reporting by the subject) was reported as 35-78%.60  In human hyperglycemic, pre-
diabetic patients, hypertonicity has been shown to be a risk factor for progression to diabetes 
mellitus, with hypernatremia having an independent effect on disease progression.64  In diabetic 
dogs and cats, the prevalence of effective hyperosmolality was reported as 81%.46  Interestingly, 
in diabetic animals, sodium (Na) concentrations appear to be more closely associated with 
osmolality (tonicity) than glucose, emphasizing the importance of sodium in diabetic 
patients.46,54 
Clinically, tonicity can be difficult to quantify because this value not only includes solute 
concentrations but also encompasses the physiologic effects of multiple solutes on the cell.  
Tonicity can be approximated by osmolality (OsM), the number of total solutes or osmoles per 
kilogram solvent. In biologic (i.e. aqueous) solutions, osmolality is equivalent to osmolarity 
(osmoles/l solvent), which can be measured directly (measured osmolality, OsMM) or calculated 
using commonly measured laboratory values (calculated osmolality OsMC, Eq. 3.1).  However, 
OsMM is a quantification of all osmoles in solution, both effective and ineffective, without regard 
to tonic effect and thus may overestimate tonicity.  An alternative approach is to calculate the 
calculated effective osmolality, OsMCE, (Eq. 3.2) from commonly measured solutes known to be 
effective osmoles (sodium [Na], potassium [K], glucose).  However, OsMCE may underestimate 
tonicity because some serum osmoles that are not measured or included in the calculation may 
have a tonic effect.  Calculated total osmolality (OsMC) may fall prey to both these limitations 
because ineffective osmoles are included in its calculation (i.e. blood urea nitrogen [BUN]) and 
because some effective unmeasured osmoles may not be included in the calculated estimate.1  
Because it is impractical to measure every solute with known or possible tonic effect, true 
tonicity is almost impossible to rigorously quantify.  However, because tonicity exerts a 
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physiologic effect (changes in cell size), a physiologic measurement of tonicity would be 
preferable to absolute quantification. 
Spurious increase in red blood cell (RBC) mean corpuscular volume (MCV) is a well-
characterized lab error that occurs when blood from hypertonic patients is assessed by an 
automated cell analyzer.  In vivo, RBCs are acclimated to the hypertonic patient serum.  In vitro, 
when RBCs from hypertonic patients are placed into the isotonic analyzer media, they swell 
because the analyzer solution is relatively hypotonic to the intracellular environment causing an 
intracellular fluid shift.79  Stookey et al. (2007) exploited this “lab error” to develop a new index 
for plasma hypertonicity.  The MCV difference (dMCV) is the difference between the MCV as 
measured by an automated cell analyzer (MCVM) and the MCV calculated from a spun 
hematocrit (hct), which is performed with RBCs in the original patient plasma (Eq. 3.3).  A 
cutoff value of only 2 fl or greater for dMCV performed well as an indicator for hypertonicity 
and, when combined with elevated plasma vasopressin levels, yielded 100% sensitivity and 
specificity.80 
Use of dMCV to detect hypertonicity has not been investigated in veterinary patients.  
The purpose of the present study was to investigate dMCV as a marker for serum hypertonicity 
in dogs and to examine the relationship between dMCV and three methods of estimating serum 
tonicity: OsMM, OsMC, and OsMCE.  It was hypothesized that dMCV would be a useful marker 
for hypertonicity and that an elevated dMCV would predict hypertonicity estimated by OsMCE 
better than it would predict hypertonicity estimated by OsMM or OsMC. 
 Materials and Methods 
 Cases 
Patient records at the Kansas State University Veterinary Health Center were searched to 
identify all animals admitted to the small animal intensive care unit (SA-ICU) between February 
1, 2012 and May 16, 2012.  Records were identified using a SA-ICU charge as a search criterion 
for the hospital practice management software.g  In addition, certain SA-ICU admissions from 
November 1, 2011 to January 31, 2012 had been identified for inclusion; on several days during 
this time period, the medical record numbers of all dogs present in the SA-ICU were recorded by 
                                                
g Vetstar, Advanced Technology Corp.; Oak Ridge, TN 
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hand and subsequently screened for study inclusion.  Cases were included if the patient was a 
dog, if a complete blood count (CBC) and a biochemistry profile were performed during the 
hospital visit, and if stored serum from the biochemistry profile was available for further 
analysis.  Dogs were excluded if anemia was present.  For the purposes of this study, anemia was 
defined as a low RBC concentration ([RBC] < 5.5 M/µl) on the CBC.  This study was performed 
in accordance with the Kansas State University guidelines for animal research. 
 Clinical Pathology 
All CBCs (ethylenediaminetetraacetic acid anticoagulated blood) and serum biochemistry 
profiles were performed by the Kansas State Veterinary Diagnostic Lab Clinical Pathology 
Laboratory within 24 hours of collection. All laboratory tests were performed by certified 
medical technologists.  CBCs were performed using the Advia 2120 Hematology System;h spun 
hct using a microcentrifuge and card hct reader was included as a standard part of the CBC.  
Biochemistry profiles were performed using the COBAS C501 Chemistry Analyzer.i  Serum 
samples were then frozen at –20°C until identified for use in the study, at which point they were 
transferred to a -80°C freezer where they were stored until batch osmometry measurements could 
be made.  Serum OsMM was measured in duplicate by freezing-point depression using the Micro-
OSMETTE osmometer.j 
 Calculations 
The following values measured as part of the CBC were included in the calculation of 
dMCV: measured mean corpuscular volume (MCVM), spun hct, and RBC.  The following values 
measured as part of the serum biochemistry profile were included in serum osmolality 
calculations: Na concentration (mmol/l), K concentration (mmol/l), glucose concentration 
(mg/dl), and BUN concentration (mg/dl).  OsMC (Eq. 3.1) and OsMCE (Eq. 3.2) were determined 
using standard clinical formulas.1 






                                                
h Siemens Medical Solutions, Inc.; Malvern, PA.  OsM of the RBC diluent is 280 mOsM 
i Roche Diagnostics; Indianapolis, IN 
j Precision Systems, Inc.; Natick, MA 
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The dMCV (Eq. 3.3) was calculated by as previously reported.80 




 Data Analysis 
Continuous data are represented as median and range.  dMCV data were assessed for 
normality using the Shapiro-Wilk test.  For each method of estimating tonicity (OsMM, OsMC, 
and OsMCE), dogs were categorized into a normosmolar group (OsM < 320 mOsM) and a 
hyperosmolar group (OsM ≥ 320 mOsM).  Because only one dog would have been considered 
hypoosmolar (OsM < 280mOsM) using measured osmolality (OsMM = 279mOsM) and no dogs 
were hypoosmolar using OsMC or OsMCE, a hypoosmolar group was not included in analysis; the 
aforementioned dog was included in the normosmolar group for OsMM analysis.  For each 
method of estimating tonicity, the dMCV of the normosmolar group and the dMCV of the 
hyperosmolar group were compared using a Student’s t-test.  The ability of dMCV to predict 
hypertonicity, as estimated by each osmolality method, was determined using a receiver operator 
characteristic (ROC) curve; cutoff values to maximize sensitivity and specificity were visually 
determined.  The area under the ROC curve (AUROC) was calculated for each osmolality 
method and these were compared. 
A post hoc analysis was performed to establish a dMCV cutoff for mild hypertonicity, 
defined as OsMM ≥ 300 mOsM.  The dMCV of normosmolar (OsMM < 300 mOsM) and 
hyperosmolar (OsMM ≥ 300 mOsM) dogs were compared using a Student’s t-test; an ROC curve 
was generated and a cutoff value maximizing sensitivity and specificity was visually determined.  
All statistical analyses were performed using commercial software.k  A p-value less than 0.05 
was considered statistically significant. 
 Results 
Two hundred and eighty-nine cases were identified from the records search (n = 255) or 
previously recorded (n = 34).  One hundred and one cases were excluded because they were not 
dogs, did not have a CBC and biochemistry panel performed during hospitalization, or did not 
                                                
k Excel, Microsoft; Redmond, WA 
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have stored serum available for further analysis.  An additional 67 dogs were excluded because 
they were found to be anemic.  One-hundred and twenty-one dogs were included in the final 
analysis.  The median age of all dogs was 7.08 years (range 1 month to 16 years).  Fifty-eight 
dogs were neutered males and 44 were neutered females; 14 dogs were intact males and 5 were 
intact females.  Pertinent clinicopathologic values, measured osmolality, and calculated values 
are summarized in Table 3.1. 
 
Table 3.1  Summary statistics of pertinent clinicopathologic values, measured osmolality, 
and calculated values. 
 Median Range Reference 
Range* 
Units 
Na 149 118 – 164 147 – 154 mmol/l 
K 4.5 3.1 – 6.6 2.6 – 5.3 mmol/l 
BUN 15 4 – 212 9 – 33 mg/dl 
Glucose 109 30 – 1108 73 – 113 mg/dl 
RBC 7.15 5.52 – 9.40 5.5 – 8.5 M/µl 
hct 48 35 – 66 35 – 55 % 
MCVM 69 62 – 76 60 – 77 fl 
OsMM 307.0 279.0 – 510.5^ n/a mOsM 
OsMC 319.4 296.0 – 377.1 n/a mOsM 
OsMCE 314.4 291.1 – 344.2 n/a mOsM 
dMCV 2.37 -2.94 – 6.92 n/a fl 
*These are the reference ranges reported by the Kansas State Veterinary Diagnostic Lab, Clinical 
Pathology Laboratory. 
^This value is unlikely to be the true osmolality of the sample, as a serum osmolality of 510 
mOsM is incompatible with life, and likely represents technical error.  However, this value was 
repeatable using the freezing-point depression osmometer so it was included in the data set.  
Exclusion of this data point does not significantly alter the results of this study. 
 
 Regardless of the method used to estimate tonicity (OsMM, OsMC, OsMCE), the dMCV 






Table 3.2  Comparison of dMCV for normosmolar and hyperosmolar dogs as determined 
by three osmolality methods. 
 Normosmolar Hyperosmolar P-value 
 Median Range N Median Range N  
OsMM 2.13 fl -2.95 – 6.87 100 3.42 fl -0.17 – 6.92 21 <0.001 
OsMC 1.79 fl -2.95 – 6.25 66 3.02 fl -2.60 – 6.92 55 <0.001 
OsMCE 2.20 fl -2.95 – 6.92 99 3.55 fl -2.60 – 6.80 22 0.001 
 
ROC curves for dMCV predicting OsMM, OsMC, and OsMCE are depicted in Figure 3.1. 
 
Figure 3.1  ROC Curves for dMCV predicting hypertonicity (OsM ≥ 320 mOsM) as 





A dMCV of 2.96, 2.47, and 2.96 fl provided maximal sensitivity and specificity for predicting 
hypertonicity as estimated by OsMM, OsMC, and OsMCE, respectively.  dMCV best predicted 
hypertonicity as estimated by OsMM (AUROC = 0.7738; Table 3.3). 
 
Table 3.3 dMCV cut off for predicting hypertonicity 
 Cut-off (fl) Sensitivity (%) Specificity (%) AUROC 
OsMM 2.96 76 71 0.7738 
OsMC 2.47 67 68 0.7063 
OsMCE 2.96 73 71 0.7337 
 
 
 The finding that dMCV could predict hypertonicity defined as OsMM ≥ 320 mOsM 
prompted the question whether dMCV might predict smaller elevations in measured osmolality.  
A post hoc analysis was performed using hypertonicity defined as OsMM ≥ 300 mOsM.  The 
dMCV for hyperosmolar dogs (2.82 fl; -2.60 – 6.92 fl) was significantly larger than that of 
normosmolar dogs (0.75 fl; -2.95 – 3.50 fl; p < 0.001).  An ROC analysis was performed 
(AUROC = 0.8021; Figure 3.2); a dMCV cutoff of 1.49 fl yielded a 75% sensitivity and 76% 
specificity. 
 





 The results of this study support the hypothesis that dMCV can be used as a physiologic 
marker for hypertonicity in hospitalized canine patients.  This finding was anticipated because 
red blood cells acclimated in a hypertonic solution (i.e. patient plasma) swell when placed into 
isotonic solution (i.e. cell analyzer media).  Interestingly, dMCV predicted serum hypertonicity 
best when tonicity was estimated using measured osmolality (OsMM ≥ 320 mOsM) rather than 
calculated effective osmolality (OsMCE).  This differs from the original hypothesis: it was 
suspected that dMCV would be a better marker for OsMCE because, as a physiologic marker of 
tonicity, dMCV should only be susceptible to changes in effective osmole concentrations; it 
should not be affected by changes in ineffective osmole concentrations, such as BUN, which are 
included in OsMM and OsMC.  Indeed, dMCV did perform better for OsMCE (AUROC = 0.7337) 
than it did for OsMC (AUROC = 0.7063), which includes BUN as well as Na, K, and glucose.  
Thus, it can be inferred that dMCV is not heavily influenced by BUN and this may hold true for 
some or all other ineffective osmoles.  However, dMCV predicted hypertonicity as estimated by 
OsMM better than by either calculated method.  The difference between measured and calculated 
osmolality is known as the osmolar gap and consists of all osmoles, effective and ineffective, not 
routinely measured.  Because unmeasured osmoles are included in OsMM and because dMCV 
performs best for predicting OsMM, it is likely that at least a portion of the unmeasured osmoles 
act as effective osmoles, influencing dMCV and therefore the physiologic effects of 
hypertonicity on RBCs. 
In this study, dogs were divided into normosmolar and hyperosmolar groups using 320 
mOsM as a cutoff for OsMM, OsMC, and OsMCE.  This value was initially chosen in order to 
include only dogs with clinically relevant hypertonicity in the hyperosmolar group.  However, in 
certain situations, it may be useful to identify mild hypertonicity as is the case in humans in 
whom it was shown that mild hypertonicity (OsMM ≥ 300 mOsM) was a risk factor for frailty in 
the elderly and for progression of disease in pre-diabetic patients.63,64  Therefore, the canine data 
were reexamined to determine dMCV performance when mild hyperosmolality is present.   
Using a lower cutoff for dMCV ( ≥ 1.5 fl) for mild hypertonicity (OsMM ≥ 300 mOsM) 
performed as well as the higher dMCV cutoff (≥ 3 fl) did for overt hypertonicity (OsMM ≥ 320 
mOsM).  This gradated cutoff system may be useful in future longitudinal studies investigating 
disease progression or markers for various morbidities. 
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 It is important to recognize that RBC size is not solely governed by tonicity, so changes 
in erythrocyte volume in response to hyper- or hypotonicity are complex and may be different 
than anticipated.  Part of this phenomenon may be due to the biconcave shape of the mammalian 
erythrocyte.  Changes in cell volume alter the conformation of the erythrocyte cytoskeleton 
leading to a change in cell membrane cell curvature.81  Therefore, if cell volume is derived from 
measurements of cell diameter, volume may be underestimated.  In the present study, RBCs were 
subjected to ‘sphering’ treatment to produce homogenous spheres by the cell analyzer prior to 
analysis, so biconcave structural effects were eliminated.  The sphering technique is standard 
practice for most RBC analyzers and has been shown to render accurate and repeatable 
measurements of RBC size.82  Plasma and intracellular proteins exert an effect on fluid balance 
through oncotic pressure, which varies according to size, structure, and charge of the protein 
moieties.  Because changes in net oncotic pressure can elicit fluid shifts independently of 
tonicity, plasma protein concentrations may alter cell size (in either direction) from values 
predicted based on plasma tonicity alone.1  Albumin is the most important plasma determinant of 
oncotic pressure, contributing approximately 80% of the total plasma colloid osmotic pressure.1  
Finally, and most importantly, all mammalian cells have the ability to regulate volume through a 
variety of active processes, which allow the cell to acclimate during periods of osmotic stress as 
well as participate in a variety of metabolic functions.2,14,17,85  The cellular compensation for 
hypertonic-induced cell shrinkage is termed regulatory volume increase (RVI) and the response 
to hypotonic-induced cell swelling, regulatory volume decrease (RVD).14,85  Early responses to 
cell shrinkage or swelling include increased membrane ion transport followed by transport of 
small nonionic organic molecules (osmolytes) including alcohols, methylamines, and amino 
acids.  These compensatory mechanisms precipitate a partial RVI or RVD within seconds to 
minutes of initial fluid shifts.  The late response to tonic change involves activation (or 
inhibition) of a variety of cellular pathways that lead to the production of heat shock proteins and 
to novel synthesis of intracellular osmolytes.  These processes require up- or downregulation of 
gene expression, so complete volume compensation (RVI or RVD), if it occurs, takes hours to 
days.2  In this study, cell volume (MCVM) was measured using an automatic cell analyzer, which 
completes its analysis within seconds.  Therefore, it can be expected that any compensatory 
volume regulatory changes would be incomplete and measured cell volume would still reflect 
initial fluid shifts caused by tonic insult to the cells. 
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 There are several limitations to the present study.  First, the determinants of dMCV (hct, 
RBC, and MCVM) were measured in plasma, whereas osmolality, electrolyte, BUN, and glucose 
measurements were made in serum, which may have affected associations between dMCV and 
the various methods of estimating tonicity.  Ideally, all measurements would have been made in 
plasma because plasma is a better representation of the in vivo environment; however, serum is 
the preferred sample type for measurement of electrolytes and plasma samples were not available 
at the time of sample retrieval for most dogs.25  Another concern is that prolonged storage of 
frozen samples could introduce artifact in the measurement of serum osmolality.  To the authors’ 
knowledge, stability of frozen canine serum for osmometric analysis has not been reported.  
However, a prospective study that examined dMCV and serum osmolality using fresh samples 
analyzed concurrently showed results consistent with those reported here (Reinhart, 
unpublished), suggesting the effect of storage is minimal.  In this study, all blood samples were 
collected during SA-ICU hospitalization, but timing of collection was not standardized.  It is 
likely that some patients received treatment prior to sample collection; the number and degree of 
interventions performed prior to collection also likely varied among patients.  This limitation 
does not weaken the ability of dMCV to predict hypertonicity, but the summary data presented 
for dMCV, osmolality, and various clinicopathologic values should not be considered 
representative of a general SA-ICU population at admission.  Ideally, all blood collection would 
have been performed at presentation prior to treatment; however, this was precluded by the 
retrospective nature of the study.  Similarly, the dogs in this study are a heterogeneous 
population of various breeds, ages, and disease processes.  Future studies could include 
assessment of tonicity in specific disease states such as diabetes mellitus; in general survey 
populations stratified by breed, sex, or age; in hospitalized populations stratified by disease 
category or severity; or in longitudinal studies tracking changes in tonicity over time, with 
disease progression, or during treatment. 
 In conclusion, the results of this study support the use of dMCV (≥ 3 fl) a physiologic 
marker for overt serum hypertonicity (OsMM ≥ 320 mOsM) in dogs.  dMCV predicts 
hypertonicity estimated by measured osmolality better than by either calculated method, 




Chapter 4 - Mean Corpuscular Volume Difference (dMCV) as a 
Marker for Serum Hypertonicity During Water Deprivation in Dogs 
Jennifer M. Reinhart, Misty R. Yancey, Lisa M. Pohlman, Thomas Schermerhorn 
 Abstract 
Introduction – The mean corpuscular volume difference (dMCV) is a novel technique that 
assesses tonicity by measuring the physiologic response of red blood cells to tonic stress.  
Increased dMCV has been suggested as a marker for hypertonicity in dogs, but has not been 
evaluated prospectively. 
Objective – The purpose of this study was to evaluate dMCV as a marker for hypertonicity 
induced by water deprivation. 
Animals – Five healthy, research colony, Greyhound dogs. 
Methods – Water was withheld for 24 hours and blood and urine were collected every six hours.  
Serum and urine osmolality were measured by freezing point depression and dMCV was 
calculated from routine hematologic parameters. 
Results – Serum and urine osmolality both significantly increased and body weight decreased 
over time as is expected in healthy dogs during water deprivation, although the increase in serum 
osmolality was mild in most dogs.  dMCV also increased over time, but  was not statistically 
different from baseline at 24 hours.  However, there was a significant correlation between serum 
osmolality and dMCV; a dMCV cut-off of 5 fl yields 100% specificity for predicting 
hypertonicity when hypertonicity is defined as serum osmolality ≥ 310 mOsM. 
Conclusions – dMCV may be a useful marker for detection of mild hypertonicity in dogs and 
may have clinical and research applications for screening for hypertonicity in canine populations. 
 Introduction 
Hypertonicity is a physiologic state of increased extracellular solute load causing water to 
shift out of cells by osmosis, which is known or suspected to have a role in numerous human and 
veterinary diseases.1,46,54,61  Hypertonicity negatively impacts cellular function but tonicity is 
difficult to quantify in a clinical setting because it is the numeric sum of all effective osmole 
concentrations, not all of which are easily identified and measured.14,15  Rather than attempting to 
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quantify individual solute concentrations, it is possible to infer total tonicity from a physiologic 
effect on cell size.86  Spurious elevation of erythrocyte mean corpuscular volume (MCV) occurs 
when blood from hypertonic patients is assessed by an automated cell analyzer.  Red blood cells 
(RBC) acclimated to hypertonic patient plasma, swell due to uptake of extracellular fluid when 
placed in isotonic media used in automated analyzers because the analyzer solution is relatively 
hypotonic to the RBC intracellular environment.79  Stookey et al. (2007) exploited the 
physiologic basis for the autoanalyzer error to develop the ‘dMCV’ as an index for plasma 
hypertonicity.80  The dMCV value is the difference between the MCV as measured by an 
automated cell analyzer (MCVM) and the MCV calculated using the value for the spun 
hematocrit (hct), which is performed with RBCs in the original patient plasma.80 
In a recent retrospective study, we demonstrated that dMCV is a marker for hypertonicity 
in dogs.86  We found that dMCV ≥ 3 fl predicted hypertonicity with a moderate sensitivity and 
specificity (76% and 71%, respectively) when total serum osmolality was ≥ 320 mOsM.86  
Although serum osmolality is an approximation of tonicity, it likely overestimates tonicity by 
inclusion of ineffective osmoles such as urea.1  The relationship between osmolality and tonicity 
is further obscured by the fact that the tonic nature of many solutes has not been defined.  Given 
these difficulties, an in vivo model of induced hypertonicity is needed to further validate dMCV 
as a hypertonicity marker in dogs.  In the normal dog, hypertonicity can be induced by oral fluid 
restriction.87  Because hypertonic plasma stimulates vasopressin release, increased plasma 
vasopressin would verify the presence of hypertonicity.  At this time, direct measurement of 
vasopressin is not possible because a canine assay is not commercially available.  However, 
release of vasopressin can be indirectly assessed by documenting an increase in urine 
concentration after a hypertonic stimulus.  Therefore, production of concentrated urine can be 
used to verify a hypertonic state during water deprivation and allow for controlled assessment of 
dMCV as a marker for hypertonicity. 
The purpose of the present study was to validate dMCV as a marker for hypertonicity in 
dogs and to determine a cutoff value for dMCV that indicates hypertonicity.  We hypothesized 
that dMCV would increase with induction of hypertonicity during water restriction and that a 
dMCV value of ~3 fl would be a useful cutoff for identification of serum hypertonicity. 
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 Materials and Methods 
Water was withheld for 24 hours from five clinically healthy Greyhound dogs (three 
male, two female), each five years old, with body weights that ranged between 33.4 – 40.7 kg.  
For each dog, body weight was recorded and blood and urine samples collected prior to water 
withdrawal (time 0) and every six hours during the 24 hour study period.  For each dog, 
maximum dehydration was limited to 5% (based on 5% loss of body weight).  A dog was 
withdrawn from the study if at any time weight loss exceeded 5% of initial body weight.  This 
study protocol was approved by the Kansas State University Institutional Animal Care and Use 
Committee. 
Routine hematologic parameters were determined using an automated cell analyzerl and 
manual hematocrit using a microcentrifuge and card reader.  The dMCV was calculated as 
previously described: dMCV = MCVM – (hct x 10)/[RBC].80,86  Blood urea nitrogen (BUN) and 
sodium concentrations were determined using a clinical biochemistry analyzerm.  Serum 
osmolality (OsMS) and urine osmolality (OsMU) were measured using a freezing point 
depression osmometern. 
The effect of water deprivation over time on body weight, BUN, sodium, OsMS, OsMU, 
and dMCV was assessed with the Friedman’s test for repeated measures and Tukey test for post 
hoc multiple comparisons.  Effectiveness of the water deprivation model to induce hypertonicity 
was determined using body weight, OsMS, and OsMU trends.  To evaluate the validity of OsMS 
as a surrogate standard for tonicity, BUN was monitored to evaluate the contribution of 
ineffective osmoles to OsMS and sodium was monitored to evaluate the contribution of effective 
osmoles. The Pearson correlation coefficient was calculated to determine the association between 
OsMS and dMCV.  A receiver operator characteristic curve (ROC) was generated to assess the 
ability of dMCV to predict mild hypertonicity and sensitivity, specificity, and area under the 
curve (AUROC) were calculated.  For the purposes of the ROC analysis, mild hypertonicity was 
                                                
l Advia 2120; Siemens Medical Solutions, Inc.; Malvern, PA 
m COBAS C501; Roche Diagnostics; Indianapolis, IN 
n Micro-OSMETTE; Precision Systems, Inc.; Natick, MA 
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defined as OsMS ≥ 310 mOsM.  All statistical analyses were performed using commercial 
softwareo.  A p-value ≤ 0.05 was considered significant. 
 Results 
 Body weight (p < 0.001) decreased significantly over time, but no dog exceeded 5% loss.  
OsMS (p = 0.02) and OsMU (p = 0.01) increased significantly over time (Figure 4.1). 
Figure 4.1  Changes in mean serum and urine osmolality over time.  
 
* denotes osmolality statistically different from baseline (time 0 hrs). 
 
The dMCV increased in 4 of 5 study dogs after 24 hours water deprivation.  Mean dMCV also 
increased over time, nearly doubling in 24 hours, but this increase did not reach statistical 
significance (p = 0.53; Figure 4.2). 
  
                                                




Figure 4.2  dMCV change over time in response to water deprivation for individual dogs 
(A-E) and mean dMCV at each time point. 
 
However, dMCV was positively correlated with OsMS (r = 0.71; p < 0.001; Figure 4.3). 
 
Figure 4.3  Scatterplot of OsMS compared to dMCV for all dogs at all time points 
demonstrating a strong correlation (r = 0.71; p < 0.001). 
 
 
The AUROC for dMCV predicting mild hypertonicity (OsMS ≥ 310 mOsM) was 0.84.  A dMCV 
cutoff for dMCV of 3 fl yielded 100% sensitivity and 31% specificity.  A cutoff of 5 fl yielded 
64% sensitivity and 100% specificity.  There was no significant change in BUN during the study 




The results of this study suggest that dMCV is a useful marker for serum hypertonicity in 
dogs.  Body weight decreased while OsMS and OsMU increased significantly during water 
deprivation.  The increase in OsMU is likely a result of hypertonic stimulation of vasopressin 
release and can be considered an indirect indicator of plasma hypertonicity.  Thus, based on 
physiologic changes documented in the study dogs, water deprivation is an effective model for 
induction of hypertonicity in the dog.  Although not statistically significant, mean dMCV 
increased over time (Figure 4.1), which is the expected response of RBCs sampled from 
hypertonic dogs.86  Given that dMCV increased in four of five study dogs and the mean dMCV 
increased by nearly 100% within 24 hours, it is possible that the effect of hypertonicity on 
dMCV is real but the sample tested (five dogs) was not large enough to detect it.  Alternatively, 
in healthy dogs, the tonic stimulus induced by 24 hours of water deprivation may not be strong 
enough or persist long enough to elicit a significant dMCV change in healthy dogs.  Serum 
tonicity is tightly regulated by the hypothalamic-renal axis, which appeared intact in these study 
dogs as evidenced by increasing OsMU.1  Thus, compensatory water resorption by the kidney 
under the influence of vasopressin may have been adequate to offset hypertonicity induced by 
water restriction.  This is likely the case as the increase in OsMS, although significant, was mild 
in most dogs (Figure 4.1).  Many veterinary diseases blunt the tubular response to vasopressin 
(secondary nephrogenic diabetes insipidus) allowing overt hypertonicity to occur so the effect on 
dMCV in clinical patients might be easier to observe.1 
A significant correlation was observed between dMCV and OsMS.  As previously 
discussed, OsMS is less than ideal as a gold standard for tonicity measurement, but in healthy 
dogs it may be an appropriate surrogate index.  Quantitatively, the difference between osmolality 
and tonicity is the total concentration of ineffective osmoles.  In health, the major ineffective 
serum osmole is urea and the major effective osmole is sodium.  Urea did not significantly 
change during water deprivation while sodium significantly increased over time, which suggests 
that the observed OsMS increase was caused by increased concentrations of effective osmoles.  
Tonicity is determined by summation of all effective osmole concentrations; therefore, in normal 
dogs, it is appropriate to use OsMS in lieu of tonicity for validation of dMCV.  The ROC analysis 
yielded two useful dMCV cutoff values.  All dogs with a dMCV ≤ 3 fl were normotonic at the 
time of measurement.  Conversely, a dMCV ≥ 5 fl yielded 100% specificity for hypertonic 
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serum.  dMCV values of 3-5 fl may be difficult to interpret without clinical context.  The ROC 
analysis was designed to detect mild hypertonicity, defined as OsMS ≥ 310 mOsM, which 
represents an increase in OsMS of less than 5% (normal canine OsMS = 300 mOsM).1  Thus a 
dMCV value ≥ 5 fl predicts hypertonicity, which can be mild, but mild tonic increases may not 
always be detected.  Ideally, the analysis would have been designed to detect overt hypertonicity 
(OsMS ≥ 320 mOsM), which is more likely to be clinically relevant; however, hypertonicity of 
this magnitude was rarely observed in the healthy dogs, presumably because the compensatory 
response to tonic stimulation was effective. 
The results of the present study are similar to those from a recently published study from 
our group in which dMCV ≥ 3 fl predicted hypertonicity with moderate sensitivity (76%) and 
specificity (71%) in a group of dogs with various clinical illnesses.86  The difference in 
sensitivity using a 3 fl cut-off for dMCV between healthy and clinically ill dogs (100% vs. 76%, 
respectively) may reflect differences in serum solute compositions of the study populations.  The 
previous study evaluated hospitalized canine patients in the intensive care unit, some of which 
had increased ineffective osmole concentrations (e.g. BUN).  Because the presence of ineffective 
osmoles increased OsMS in the canine patients studied, OsMs was less likely to be a useful 
surrogate for tonicity than OsMS in the healthy dogs used the present study.  
Analysis demonstrated a moderate, but significant, positive correlation between dMCV and 
OsMS in healthy dogs.  As previously discussed, dMCV is insensitive to minor or short-term 
alterations in serum tonicity, which may explain why the correlation between dMCV and OsMS 
was not stronger.  However, the dMCV may provide information that other estimates of tonicity 
do not because not only does dMCV respond to increased effective osmolar concentration but it 
incorporates the functional effects of hypertonicity on cells. Thus, the dMCV represents the 
physiologic implications of tonic derangements and provides superior information over purely 
quantitative estimates, such as the OsMS value. 
Although hypertonicity develops in many canine diseases, the clinical significance of 
hypertonicity is unclear in most situations.  dMCV is a novel marker for serum hypertonicity 
that, in conjunction with osmolality and solute concentration assessment, may better elucidate 
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Appendix A - Abbreviations 
AA  acetoacetate 
ADH  antidiuretic hormone 
AKI  acute kidney injury 
ANP  atrial natriuretic peptide 
AQP  aquaporin 
ATP  adenosine triphosphate 
AUROC area under receiver operator curve 
BNP  brain natriuretic peptide 
BHB  β-hydroxybutyrate 
BUN  blood urea nitrogen 
Ca2+  calcium 
CBC  complete blood count 
CDI  central diabetes insipidus 
CNP  C-type natriuretic peptide 
Cl-  chloride 
CNS  central nervous system 
D5W  5% dextrose in sterile water 
DKA  diabetic ketoacidosis 
DM  diabetes mellitus 
dMCV  mean corpuscular volume difference 
DNA  deoxyribonucleic acid 
dRBC  red blood cell diameter 
ECF  extracellular fluid 
EDTA  ethylenediaminetetraacetic acid 
EG  ethylene glycol 
fl  femtoliter 
GABA  γ-aminobutyric acid 
GFR  glomerular filtration rate 
GIT  gastrointestinal tract 
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GLUT  glucose transporter 
H+  hydrogen 
H50  50% hemolysis sucrose concentration 
HCO3-  bicarbonate 
hct  hematocrit 
HHS  hyperglycemic, hyperosmolar syndrome 
ICF  intracellular fluid 
JGA  juxtaglomerular apparatus 
K+  potassium 
Li+  lithium 
MCT  monocarboxylate transporter 
MCV  mean corpuscular volume 
MCVM  measured mean corpuscular volume 
Mg2+  magnesium 
MNC  magnocellular neurosecretory cells 
Na+  sodium 
NDI  nephrogenic diabetes insipidus 
OsM  osmolality 
OsMC  calculated osmolality 
OsMCE  calculated effective osmolality 
OsMM  measured osmolality 
OsMS  serum osmolality 
OsMU  urine osmolality 
RAAS  renin-angiotensin-aldosterone system 
RBC  red blood cell 
ROC  receiver operator characteristic 
RVD  regulatory volume decrease 
RVI  regulatory volume increase 
SA-ICU small animal intensive care unit 
SIADH syndrome of inappropriate secretion of antidiuretic hormone 
UT-A  urea transporter A 
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UT-B  urea transporter B 
 
